User talk:Sbharris/archive10

Archive #10 All messages from entire year of 2011.

File source problem with File:HollidayLcollar2.jpg
Thank you for uploading File:HollidayLcollar2.jpg. I noticed that the file's description page currently doesn't specify who created the content, so the copyright status is unclear. If you did not create this file yourself, you will need to specify the owner of the copyright. If you obtained it from a website, please add a link to the website from which it was taken, together with a brief restatement of that website's terms of use of its content. However, if the copyright holder is a party unaffiliated from the website's publisher, that copyright should also be acknowledged.

If you have uploaded other files, consider verifying that you have specified sources for those files as well. You can find a list of files you have created [ in your upload log]. Unsourced and untagged images may be deleted one week after they have been tagged per Wikipedia's criteria for speedy deletion, F4. If the image is copyrighted and non-free, the image will be deleted 48 hours after 04:18, 1 January 2011 (UTC) per speedy deletion criterion F7. If you have any questions or are in need of assistance please ask them at the Media copyright questions page. Thank you. Magog the Ogre (talk) 04:18, 1 January 2011 (UTC)

ANSWER:

File source is:

http://www.chronicleoftheoldwest.com/pics/doc-_holliday400.jpg

Subject is way predated from 1923. It is 1882 or so, and subject died in 1887. S B Harris 20:49, 1 January 2011 (UTC)

BioAs
Maybe you would take a look at Arsenic biochemistry, which is kinda of to a weird start. The contributing editors are fascinated by the prospect that As could replace P in nucleotides and/or ATP (a recent Science paper). But there is a body of literature on organoAs compounds in nature, which I will find. There is some literature on some therapeutic benefits of sublethal amts of As, perhaps in stimulating biosynthesis of heme or something like that, that I though you might be able to locate. It takes me days to get to these projects so no rush. I found this on my computer which looks nifty if you have on-line access to Nature, doi:10.1038/nrc887, taken from Arsenic trioxide. If you are unable to help, no problem, the thing is that you have relatively unusual expertise within Wikipedia.

Anyway, did you find any textbook material on essential fatty acids?.--Smokefoot (talk) 01:32, 4 January 2011 (UTC)

Xenon/Fluorine compounds
The table you give at Noble gas compound is incomplete. For example the XeF5+ and Xe2F11+ ions exist, as do a wide variety of other compounds (e.g. perfluorophenylxenone tetrafluoroborate (C6F5Xe+.BF4-), or nitronium tridecafluorodixenate (NO2+.Xe2F13-)).

The nature of the product of xenon and platinum hexafluoride is uncertain. It is thought to be a mixture of various compounds included XeF+.Pt2F11-. As far as I can tell there is no (other) evidence of a chemically stable Xe+ ion (as opposed to the dixenon ion Xe2+). Lavateraguy (talk) 11:28, 19 January 2011 (UTC)


 * WP:SOFIXIT. The xenon-platinum hexafluoride adduct has its own article, due to its complexity and its importance in history. We can and should refer to it in tables like this one (nature uncertain: see xenon hexafluoroplatinate). It's not my table, but one I removed from the fluorine article where it was cluttering things up by overexpanding the too-large noble gas compounds section. It needs addition of not only the compounds you mention, but (considering where I moved it) also compounds of noble gases with other elements as well (which are so rare that all together they probably don't number as many as are already in this table). See http://en.wikipedia.org/wiki/Category:Xenon_compounds and also the long list of compounds in xenon including fluorine-free oxides and other stuff. S  B Harris 21:42, 19 January 2011 (UTC)

Your constructive edit to Heat
Thank you for your correction to the article Heat. I will not revert it.Kmarinas86 (Expert Sectioneer of Wikipedia) 19+9+14 + karma = 19+9+14 + talk = 86 23:30, 19 January 2011 (UTC)

File source problem with File:Schieffelin2.JPG
Thank you for uploading File:Schieffelin2.JPG. I noticed that the file's description page currently doesn't specify who created the content, so the copyright status is unclear. If you did not create this file yourself, you will need to specify the owner of the copyright. If you obtained it from a website, please add a link to the website from which it was taken, together with a brief restatement of that website's terms of use of its content. However, if the copyright holder is a party unaffiliated from the website's publisher, that copyright should also be acknowledged.

If you have uploaded other files, consider verifying that you have specified sources for those files as well. You can find a list of files you have created [ in your upload log]. Unsourced and untagged images may be deleted one week after they have been tagged per Wikipedia's criteria for speedy deletion, F4. If the image is copyrighted and non-free, the image will be deleted 48 hours after 19:43, 26 January 2011 (UTC) per speedy deletion criterion F7. If you have any questions or are in need of assistance please ask them at the Media copyright questions page. Thank you. Magog the Ogre (talk) 19:43, 26 January 2011 (UTC)

Thank you for the one liners
I just want to thank you for teaching me some cool one liners in our brief but heated exchange on the Science Talk Page. Since then, I have enjoyed using colorful phrases such as "stop teaching me to suck eggs." It has enriched my interactions with other people, in real life and online. Thanks again and I hope there are no hard feelings from that time. Cheers. mezzaninelounge (talk) 23:50, 26 January 2011 (UTC)

Fluorine
Thanks for your time to work on the fluorine article! I try to find the right words but most of the time I fall short of the goal that everybody else can understand what I want to say. There are a lot of points in the article which have to be improved before it is GA or FA level. --Stone (talk) 06:37, 28 January 2011 (UTC)


 * Bitte sehr. On en.wiki I think we generally have a good idea of what you want to say, but occasionally it's not quite the best way to put it, in English. But collaboration is what Wikipedia is for. We need you more for your knowledge of chemistry than for your elegant prose. As for fluorine, it occurs to me that the problem is that it is chamelion, doing something different in almost every molecule where it occurs. Its affinity for electrons gives it effects that are far-reaching and that vary from element to element near it. In covalent molecules it violently draws electrons out of the rest of the molecule, then presents a "surface" of its own to other atoms that is as slippery as an inert gas. It's this combination of reactivity and inertness that makes all these things so difficult to describe. But I think that slipperiness is the metaphor that ties fluorine compounds together better than any other, and that idea occurs in its name (translated from German Flusse), and this is ultimately no accident. So we can tie all this together into one good story. S  B Harris 00:25, 29 January 2011 (UTC)


 * Nice edits. I will try to have another look this in the next 24 hours. --John (talk) 06:24, 6 March 2011 (UTC)

Talkback
--  HJ Mitchell  &#124;  Penny for your thoughts?   20:15, 1 February 2011 (UTC)

ArbCom
Your name has been mentioned in recent evidence for an arbitration case filed on 2010-11-18. You were not originally named as a party, but I am sending this notice proforma to editors named in evidence, before the workshop period closes. If you wish to do so, enter your statement and any other material you wish to submit to the Arbitration Committee at Arbitration/Requests/Case/Longevity/Workshop, or elsewhere on that page or the case's four talk pages. Additionally, the following resources may be of use— Thanks, JJB 21:06, 3 February 2011 (UTC)
 * Arbitration/Requests;
 * Arbitration guide.

Neon isotopes
Hello. I would be interested in your reaction to my comments at Talk: Neon about the Isotopes section. It is quite confused and I have made a number of suggestions, but I am not confident that I have everything straight. In particular I am not certain exactly what is and is not included in the term "nucleogenic". If I have that wrong some of my suggestions will have to be modified. Dirac66 (talk) 01:12, 14 February 2011 (UTC)
 * Hi. Yeah, this was complicated. It helped me to find the USGS source from which the section on heavy neon isotopes was cribbed, and I found that it was badly written, talking about alpha sources and alpha emissions at the same time. In addition, whoever used it (not me!), had misinterpreted the (n,alpha) in it, to mean "neutron-emission, alpha-decay," when it's actually neutron-capture, alpha emission (one nuclear reaction that doesn't really involve a conventional alpha decay, but more like an alpha knockout). I had to go and write a stub on nucleogenic isotopes (those that arise on earth from natural nuclear reactions not involving cosmic rays). It's confusing since nuclear reactions are ultimately responsible for the nucleosythesis of most primordial nuclides, but all that is much further in the past, and it's convenient for geologists to separate out those that have happened since the Earth condensed, since they can learn about geological processes that way. So "nucleogenic" is a term reserved for products of nuclear reactions that happen on Earth. Anyway, I've re-written the neon isotope section. See if it doesn't make more sense, now. S  B Harris 05:39, 14 February 2011 (UTC)
 * Thanks. Neon#Isotopes is much clearer now, and the article on Nucleogenic helps a lot. Much of my confusion was due to misunderstanding this term. As for "not me!", I knew you didn't write the previous version because I know that you write much more clearly than that. Dirac66 (talk) 16:32, 14 February 2011 (UTC)

Edit summaries
You forgot to add edit summaries to several of your edits to the Gunfight at the O.K. Corral. It helps others to know what's going on with the article. Thanks. -- btphelps (talk) (contribs) 00:54, 19 February 2011 (UTC)


 * Sorry. It's a chronic bad habit of mine. Mostly nobody is watching my edits as closely as you're watching mine at the moment, I suppose. I'll be more talkative. S  B Harris 01:03, 19 February 2011 (UTC)

OK
ceOk, but you may have been a bit nicer. I just didn't know that it would erase all the in-between edits. At least that I'v learned more about Wikipedia. Awsome EBE123(talk | Contribs) 18:52, 19 February 2011 (UTC)


 * Sorry to jump on you, but this cost me some time, and was annoying. I assumed that after being here a year and making a thousand edits, you'd have learned this by now. Yes, whenever you bring up a previous version of an article and save it, everything else is written over (this is a good way to erase a lot of vandalism, if ALL of it is past a certain version-- you just go back to the pre-vandal version and save that. If you save a previous version with good edits after it, that's usually not a problem if somebody notices this immediately, and does the reverse to YOUR edit. But if you do this and then a bunch of editors add new stuff AFTER you without noticing that you've taken out a lot of good edits (as in the fluorine article), it becomes difficult to disintangle, since good edits are mixed in with bad ones. Cheers. S  B Harris 19:37, 19 February 2011 (UTC)

Creating a new talk section
Your are doing it wrong, either making no edit summary, or even worse, making an incorrect (misleading, disinformating) summary. Use the new section feature. Unlike writing a descriptive edit summary manually, in this case the engine will do it for you automatically – just press the button and enter a section heading to webform.

P.S. I hope, reply on my talk page is not required, I partially answered to your bids at Talk:Hydron (chemistry). Incnis Mrsi (talk) 11:34, 27 February 2011 (UTC)

Missing edit summaries
I see that you are a significant contributor to a large variety of articles on Wikipedia. You have an amazing range of interests! However, you continually make significant edits without leaving an edit summary, making it more challenging and time-consuming for others to learn about what changes you made. I found these examples within the past three days: here, here, here, here, and here.

Because you make so many contributions, you may occasionally experience challenges in resolving conflicting edits with other Wikipedians. As per Wikipedia guidelines. "Proper use of edit summaries is critical to resolving content disputes. Edit summaries should accurately and succinctly summarize the nature of the edit, especially if it could be controversial."

It would be very helpful to other Wikipedians if you will take a few more seconds when you complete an edit to add an edit summary. "Doing so helps everyone understand the intention of your edit (and prevents legitimate edits from being mistaken for vandalism). It is also helpful to users reading the edit history of the page." For your convenience, you can use a number of abbreviations. I know I would appreciate the courtesy of being able to scan edit summaries for the latest changes. Regards, -- btphelps (talk) (contribs) 19:58, 1 March 2011 (UTC)

Why you (Sbharris) delete my article about Max GXL in Wikipedia.
i will like to know who in Gods name give the right to anyone to edit/undo whatever he may find he can/will, i am not making publicity for any firm, i am not making money myself telling the world that glutathione levels can be raised in a ease way, there is not a phone number or a website url in there and everything is for informational purposes, myself and my parents have been beneficiated by this formula in a marvelous way and after doing a little research i just want the world to know about the wonders of glutathione in the body of anyone suffering from a lot of illnesses not so easy to be help like fibromyalgia and arthritis-arthrosis between others, what is wrong with that?, i `ll wait for your answer, 69.136.22.87 (talk) 22:38, 6 March 2011 (UTC)


 * What is wrong with it, is that you cannot prove it just by saying it. You need to understand how Wikipedia works. It is not an advertising amplifier for people in multilevel marketing schemes to push supplements. We don't care about your testimonials. We want citations to published studies in journals-- really good published studies. Find some, reference them, and you can add the information to the section on the article about raising glutathione with supplements (although why you'd pay all this money for Max GXL when all of its ingredients are available cheaply from NOW or Puritan's Pride is beyond me). You added claims but no studies or references for them. Now, be sure you look up all about Max GXL on the web, including who runs it. Are they legit? Do they have reputations for honesty? Or do they claim they can cure AIDS and when you look at them, they are involved in securities fraud? . The company website looks like the typical self-promo multi-level marketing BS. WWW.scam comments:

First off.. if MaxGXL is a breakthrough medical technology that soon, "everyone in the world will be taking Max", then why doesn't Google News show any hits when you search for it. Its hard to believe that something thats been out for a year that is reputed to be so amazing, has not gotten picked up by a mainstream media outlet.

Here are some of the people who I've seen are involved.

Fred Ninow - founder Steven Scott - founder Greg Fullerton - founder

( http://www.cnssecuritieslaw.com/(S(0ajgt455omc3amvca0x3k145))/LawReport/ViewReport.aspx?Report=31&Category=3 )

Salt Lake County District Court 080901295 Brad Johnsen; William Tolbert; Bud Corkin; George W. Cannon; Douglas S. Simpkins; Kirk Jenkins v. ISP Services LLC; Max Software Inc.; Max International LLC; Fred Ninow; Steven K. Scott; Greg Fullerton

A software company specializing in filtering pornographic material from DVDs and the Internet allegedly duped a group of Mormons into investing $285,000 in the company, and then refused to return the funds.Greg Fullerton, manager of ISP Services, promised up to 400 percent returns and predicted that annual sales would exceed $540 million, according to a lawsuit filed against the company and its directors.

Fullerton falsely claimed that ISP had created infomercials featuring Chuck Norris and Patricia Heaton, who stars on “Everybody Loves Raymond,” and that Oprah planned to feature ISP on her show, according to the complaint. The manager also falsely asserted that high-ranking members of the Church of the Latter Day Saints had endorsed the company, and that several Christian networks had contracted with ISP to market the corporation’s DVD players.

The “cash cow” company failed to produce any net income, however, and investors now seek $1 million in punitive damages for Fullerton’s alleged misrepresentations.According to Max International’s Web site, the defendants are now marketing a product called MaxGXL, which purportedly contains an antioxidant that detoxifies the liver and slows aging.

Causes of action: Violations of federal securities laws; fraudulent misrepresentation; breach of fiduciary duty; unjust enrichment; breach of contract Filing counsel: Jeremy Hoffman and Richard Ensor of Young, Hoffman, Strassberg & Ensor (Salt Lake City, UT) – C.G.

Patrick Ryan - southern California heavy hitter Jim Sweeney - diamond associate

Patrick and Jim were involved in a MLM named "BigCo-op, Inc." which recieved a desist and refrain order from the California department of Corporations ( malformed Google link removed ) for the following:

"BigCo-op, Inc., Ez2Win.Biz, James Sweeney, Patrick Ryan, Richard Hickey and Rick Deluca also failed to disclose to investors that a prior lawsuit had been filed on February 22, 2002 against James Sweeney and BigCo-op Inc. in United States District Court for the Western District of Washington entitled The Topline, Inc v. The Big Co-op Inc. and James Albert Sweeney, case number CV02-0434. That suit brought by participants in the BigCo-op Inc. marketing scheme contained causes of action for fraud and unfair competition in addition to causes of action for selling unregistered nonexempt stock in violation of the registration requirement of Section 12(a)(1) of the Federal Securities Act and for knowingly making material misrepresentations and ommisions in the sale of that stock in violation of Section 12(a)(2) of the Federal Securities Act. The complaint alleged that Albert Sweeney had intentionally misrepresented that the BigCo-op Inc. stock had been valued in the range of $200,000,000 by an independent auditor and that individual shares were valued at $20-40 per share when in fact the “stock was essentially worthless at all times.” That suit also alleged that the stock was promised to participants in return for bringing in new members and that monthly payments for membership fees continued to be deducted automatically from members accounts by BigCo-op, Inc. even after BigCo-op, Inc.’s website had been shut down for several months in 2001 preventing members from engaging in any profit making from their participation in the multilevel marketing program

Also, If you've met Patrick Ryan you know his whole life story, which sounds so ridiculous that it may be true. He claims he has an eighth grade education and that he was adopted by Jim Sweeney, who helped him make his first million by 19.

But how does that explain... http://web.archive.org/web/200406051...management.asp "Patrick has been closer to the formation of the BigCo-op concept than any other one person other than Mr. J. Albert Sweeney. Having been born, raised and educated in a computer-based world he understands the present-day position of the Internet in everyday life and like a "Silicon Valley Wonder Boy" he thrives on innovation and futuristic thinking. Patrick's responsibilities range from investor relations to general management while serving as the "right-hand-man" to the CEO."

Now, when taking a look at Jim Sweeneys website.. http://web.archive.org/web/200510300...e-journey.html

There is no mention of Patrick or any adoption.. interesting...

Good answer...and a lot of BS in there, i don`t care where you got this info from of who these people are or what do you intend to proof with that, all i am saying is that MaxGXL was created by Dr. Robert Keller, one of the outstanding doctors and scientist of the XX century and somebody with a reputation many doctors don`t receive in his lifetime (look for his curriculum vitae below, is impressive) and the formula DO HAVE A DOUBLE BLIND STUDY CONDUCTED by the Dr Keller himself and a COMPOSITION PATENT too, and it`s aproved by the NSF, you can find the results of the study here: http://max.com/pdf/GXLAbstract.pdf, (i don`t think that Dr Keller was so stupid in taking 10 years of his live investigating the exact proportions of the formula if you can buy the stuff from Puritan`s Pride in any quantities you like and having the same results), if you don`t find this enough you can go to PUBMED where you are going to find close to 93,000 articles writen by Doctors like yourself validating the use of Glutathione for a lot of illnesses and conditions, i have myself seen my mother getting rid of his 4 years old everyday pain from the fibromyalgia thanks to the MaxGXL and that is what i do care about, my father is being help from his legs inflammation and numbness do to the diabetes and is getting more and more energy everyday `till the point of having a penis erection for the first time in more then 15 years :-), (!!a 85 years old!!) he can sleep the whole night like a baby for the first time in 20 years, and is being help from his foot ulcers open now from a long time, i myself am still amazed about the amount of energy i am getting everyday, the mental clarity and the easyness to use my arms i am having, being myself 52 and having muscles and joint problems do to heavy work done years ago, mi little nephew is having magnificent results with his Crohn Disease and my wife is free of pain in her foots from the calcaneal spur she was having from two years now and totally relieved from the hemorrhoids she was having from a long time ago, this is what is important to me, and if i can help other people with similar problems, believe me that i`m going to do everything in my power to get it done, you should see my mother face of happiness now a days and you`ll understand what i am talking about. If Dr. Robert Keller decided to put the formula in the hands of Steven Scott and not giving it to a pharmaceutical company, he may had had his reasons in doing that, God knows why, (althought i do have my own idea why) he is already dead, so we can`t ask him about it. On the other hand i do understand that there are people making money from this product, let me tell you something, the biggest money makers from the illnesses of the American people are the big multinational pharmaceuticals companies (and you should know few of them) that are getting richer and richer everyday selling products with so many side effects that it`s incredible they be permitted to keep selling these poisons, they are so powerful that even after having created some products retired from the market for having killed people and saying in tv ads that some of them can cause dead, they keep selling it, and i haven`t see you complaining about it, both my parents are being treated with those pharmaceuticals for years expending a lot of money and time w/o being really helped by the prescriptions and yes, getting sick from few of them, and being forced to take more pills to solution the problem created from the original prescription. So if there are not so nice people involved in the distribution of the product, i can live with that, this happen in every area of our live, even in our own family, and this does not affect in anyway the results from the product that is what really matters. I have to see yet any side effect from the Max GXL we are taking for 8 months now, and believe me if i tell you that i am looking for info about glutathione for few months now w/o finding any article about side effects so far other than debilitating the effects of chemoterapy in some cases of cancer in some tumor cells, althought others studies can`t proof that claim. This is what the doctor John C. Nelson 159th President of the AMA did say about MaxGXL (and he is not involved with Max International in any way):

Dr. John C. Nelson, 159th President of the American Medical Association about Max GXL:

“This product, in my opinion, represents the single most important breakthrough in health that I will witness in my life time. I believe it will revolutionize, change, and transform the practice of medicine world-wide and make Dr Robert Keller more famous than Jonas Salk who created the polio vaccine.”

So you see, i don`t care about who is selling it and their past, all i care is from who is coming, and the results i am getting and seeing, the rest is anecdotical even if you want to write a book about it. So it seems that you are powerful enough to delete everything you`ll like, even if it`s proved that the product is legit, tested by double-blind studies, patented and supported by a lot of physicians, that`s ok with me, you may keep your attitude, i`m gonna keep trying to help people with all what i know now about glutathione in anyway i can, have a good one.

Dr Robert H keller Curriculum Vitae:

Education and Training:

Fordham University, Keating Hall 1966 Bachelor of Arts in Biology; Master of Science in Biology Fordham University, Bronx, New York

Temple University, Philadelphia, Pennsylvania 1970 Doctor of Medicine (MD) with honors Temple University, Philadelphia, Pennsylvania

University of Rochester, Rochester, New York 1970-1974 Internship, Resident and Senior Resident University of Rochester, Rochester, New York

Mayo Clinic, Rochester, Minnesota 1974-1976 Fellow and Senior Fellow Department of Immunology Mayo Clinic, Rochester, Minnesota

Mayo Clinic, Rochester, Minnesota 1976 Master of Science in Immunology Mayo Graduate School of Medicine Rochester, Minnesota

Professional and Faculty Positions:

2006 Founder, CSO and Director of Medicine KBK Institute of Advanced Medicine Hollywood, Florida

2001 Founder, Chairman, CEO & CSO Phoenix BioSciences which has developed a new first in class and first in man viral-host interaction inhibitor for HIV / AIDS

1999 Founder, Chairmain,CEO and CSO Vitimmune, Inc Hollywood, Florida

1998 Voluntary Adjunct Professor Miller School of Medicine, University of Miami Miami, Florida

1996 Chairman and CEO Immune Balance Technologies Hollywood, Florida

1994-2006 Director of Medicine & Research BIODORON Medical Center Hollywood, Florida

1994-1995 Consultant in Immunology and Hematology Health Professionals, Inc and Center for Special Immunology

1992-1995 Director Immune Reconstitution Program Center for Special Immunology

1992-1995 Medical Director Center for Special Immunology Miami Beach, Florida

1987-1996 President and Medical Director The Wilson Bode Center Fort Lauderdale, Florida

1986-1987 Associate Director of Research and Development Coulter Immunology Coulter Electronics, Inc., Hialeah, Florida

1982-1986 Medical Director Wilson Bode Center for Hematology and Immunology Research Milwaukee, Wisconsin

1982-1986 Clinical Professor Department of Health Sciences (Hematology, Immunology, Flow Cytometry) University of Wisconsin Milwaukee, Wisconsin

1982-1986 Associate Professor Departments of Medicine and Biophysics Medical College of Wisconsin Milwaukee, Wisconsin

1982-1986 Clinical Investigator and Staff Physician Zablocki VAMC Milwaukee, Wisconsin

1980-1982 Director of Immunology Midwest Children's Cancer Center (Immunology, Flow Cytometry, Transplantation) Chief of Immunology Milwaukee Children's Hospital Milwaukee, Wisconsin

1980-1982 Associate Professor Department of Pediatrics (Hematology/Oncology, Immunology) Medical College of Wisconsin Milwaukee, Wisconsin

1979-1982 Clinical Associate Professor Department of Health Sciences (Hematology, Immunology, Flow Cytometry) University of Wisconsin Milwaukee, Wisconsin

1978-1980 Research Associate and Staff Physician Research Service Zablocki VAMC Milwaukee, Wisconsin

1977-1980 Assistant Professor Department of Medicine (Hematology/Oncology) Medical College of Wisconsin Milwaukee, Wisconsin

1977 Consultant And Assistant Professor Department of Immunology Mayo Medical School Dept. of Medicine University of Minnesota

1974-1977 Fellow and Senior Research Fellow in Immunology Mayo Clinic Foundation Mayo Graduate School of Medicine Rochester, Minnesota

Hospital Staff Appointments: 1976-1977 Mayo Clinic, Rochester, Minnesota 1977-1986 Zablocki VAMC, Milwaukee, Wisconsin 1977-1986 Milwaukee County Medical Complex, Milwaukee, Wisconsin 1992-1997 Mount Sinai Medical Center, Miami Beach, Florida 1992-1999 Cleveland Clinic Hospital, Fort Lauderdale, Florida 1992-1999 Miami Heart Institute, Miami Beach, Florida 1997-1999 Palmetto General Hospital, Hialeah, Florida 1997-2005 South Shore Hospital, Miami Beach, Florida 1997-2005 Memorial Medical Center, Hollywood, Florida 1992-2009 Broward General Medical Center, Fort Lauderdale, Florida 1997-2009 Hollywood Medical Center, Hollywood, Florida

Fellowships and Awards: 1967-1969 Health Professions Scholarship Temple University School of Medicine

1974-1975 Mayo Foundation Research Fellowship Mayo Graduate School of Medicine

1975-1978 National Arthritis Foundation Fellowship

1978-1981 VA Career Development Award, Research Associate

1983-1986 VA Career Development Award, Clinical Investigator

Grant Support during Academic Tenure 1978-1980 Alpha-fetoprotein Immunoregulation in a Model of Murine Lymphoma Veterans Administration Research Principal Investigator $210,000

1981-1986 Immunoregulatory Dysfunction in Non-Hodgkin's Lymphoma NIH, NCI Principal Investigator $430,000

1982-1986 Immunologic Studies of Environmental Lung Disease NIH (NIAID) Co-Principal Investigator $525,000

1983-1986 VA Career Development Award Clinical Investigator $240,000

1984-1986 Clinical Applications of Laser Flow Cytometry Principal Investigator NIH (RR Shared Equipment Program) $105,609

1984-1987 Immunoregulatory Dysfunction Principal Investigator VA $245,000

1985-1986 Monoclonal Antibodies in the Detection of Cervical Carcinoma Co-Principal Investigator Hillman Foundation $85,000

1986-1987 Isoprinosine Modulation of the Immuno- Regulatory Imbalances in AIDS and ARC Principal Investigator of FDA IND Newport Foundation $125,000

Honors: 1970 Alpha Omega Alpha Temple University, School of Medicine

1970 Medical Degree with honors Temple University, School of Medicine

1979 Superior Performance Award in Research Veterans Administration

1980 Fellow, American College of Physicians

1991 Who's Who in Science and Technology

1994 Who's Who in the World

1996 Who's Who in Medicine and Science

1998 HIV Medical Professional of the Year PWAC, Broward County, Florida

1999 Humanitarian of the Year National Hemophilia Foundation

2001 2000 Outstanding Scientists of the 21st Century

2002 1000 Great Americans of the 21st Century

2003 America's Top Physicians in Internal Medicine, Immunology and Hematology

2004 Elected to Board of Governors

Academy of HIV Medicine of the State of Florida: 2004 AMA Physicians Recognition Award

2005 Greatest Scholars of the Twenty First Century

2006 Health Professional of the Year Invited Lectureships

1977 Second Fogarty International Conference on Neonatal Liver Disease Baltimore, Maryland

1977 International Conference on the Diagnosis and Prevention of Neural Tube Defects Los Angeles, California

1977 Second International Conference on Diagnostic Immunology Henniker, New Hampshire

1979 Radio immunochemical Detection of Cancer Albuquerque, New Mexico

1980 Visiting Professor of Hematology University of Mississippi Jackson, Mississippi

1981 Visiting Professor of Hematology University of California Irvine, California

1981 Third International Conference on Diagnostic Immunology, Section Chair

1982 Visiting Professor of Pathology University of Texas Medical Branch Galveston, Texas

1983 Visiting Professor of Medicine Wilfred Hall Air Force Research Center Galveston, Texas

1984 Visiting Professor Max Plank Institute for Biochemie Munich, Germany

2005 Visiting Professor of Immunology and Pharmacology Peking Union Medical School (University of Beijing) Beijing, China

Editorial Boards: 1986-1990 Diagnostic Immunology 1984-1986 Journal of Leukocyte Biology 2005 Interventions in Aging

Reviewer: 1990-2009 Journal of Immunology 2005 Interventions in Aging

Consultant ships: Coulter Epics Coulter Immunology Corning Scientific National Aeronautics and Space Administration (NASA) Abbott HIV Advisory Board Baxter Advisory Board for Hemophilia Baxter Advisory Board for Hemophilia Inhibitor Patients Consultant in Cancer Therapy, PRSS-J, Tokyo, 2005 Medical Advisory Council, American Federation of Hemophilia, 2002

Board of Director Appointments: 2006 Member American Academy of HIV Medicine 2006 Member Biosource Therapeutics 2001 Chairman, Phoenix Bioscience 1999 Chairman, VitImmune 1996 Chairman, IBT

Scientific Advisory Boards: 2006 Cytodyn Inc 2006 Acthelon Medical 2006 Bioscource Therapeutics

Certifications: National Board of Medical Examiners, 1971 and 1990 American Board of Internal Medicine, 1974 American Academy of HIV Medicine, 2001 American Academy of Anti Aging Medicine 2006

Current Medical Licensure: New York #112195 Wisconsin #19121 Florida #58991

Certification: ACLS 1990 ATLS 1990

Professional Societies: Alpha Omega Alpha American Association for the Advancement of Science American Association of Immunologists American College of Physicians American Federation of Clinical Research American Society of Clinical Pathology American Society of Hematology International Society of Hematology International Society of Hematopathology International Immunocompromised Host Society International Society of Analytical Cytology Clinical Cytometry Society New York Academy of Sciences Clinical Immunology Society National Organization for Rare Disorders American Academy of Anti Aging Medicine

Teaching Experience: 1978-1980 Survey in Basic and Clinical Immunology Department of Medicine Medical College of Wisconsin

1980-1983 Principles of Laser Flow Cytometry Department of Health Sciences University of Wisconsin

1981 Special Topics in Immunology Immunoregulation in Cancer Department of Biology Marquette University

1983-1986 Co-Director Flow Cytometry Program University of Wisconsin Introduction to Flow Cytometric Analysis Principles of Image and Laser Cytometry Hybridomas and Monoclonal Antibodies Laboratory Evaluation of Immunoregulation Clinical Immunophenotyping and DNA Analysis Advanced Cytometry Advanced Cytometric Techniques

Invited Professional Lectures: 1979-2009 Dr. Keller has been the invited speaker at more than 2500 state, regional, National, and international, medical and scientific seminars and workshops In the fields of:

AIDS and Immunoregulation Clinical Immunology Chronic Fatigue Syndrome and Fibromyalgia Autoimmune Disease and Control of Aberrant Immune Response Nutrition and the Immune Response Hormones and the Immune Response Hepatitis C Hemophilia Protecting the Immune System Before, During, and After Cancer Therapy. Age Management

2000-2002 Host of Today's Health, WAXY 790 and Web streamed at Vitimmune.com and RobKellermd.org

2005-2006 Host of Voice America Web Based Interactive Radio Show, The Path to Wellness and Youth

Committee Service: 1985-1986 Veterans Administration Development Research and Committee Clement J. Zablocki VAMC 1986-1989 VA Oncology Merit Review Board 1984-1986 International Society For Analytical Cytology: Research and Development 1983-1986 Controls & Standards University of Wisconsin: Co Chair Flow Cytometry 1983-1986 National Institutes of Health: Special Immunology Review Council Study Section 1980-1982 Medical College of Wisconsin Faculty Welfare Committee 1980-1982 Animal Care Committee 1982-1986 Flow Cytometry Protocol Committee 1992 Cancer Committee for Hollywood Medical Center 1998 Committee of Ten Thousand Medical Advisory Board 1996 National Hemophilia Federation: Medical Advisory Committee 1994 National Hemophilia Foundation- Florida Chapter Medical Advisory Committee 1994-1997 Mount Sinal Medical Center Cancer Committee 2001 Hollywood Medical Center Cancer Committee 2005 Underwriting Committee ProAssurance Malpractice 2005 AAHIVM Standards of Practice Committee

Statement of Research Interest: HIV: Dissection of the immune perturbations Associated with HIV infection including therapy with experimental immunomodulary agents.

Dissection of the immune perturbations Associated with hemophiliac complication and therapeutic intervention using experimental immunoregulatory agents.

Creation and utilization of unique `designer` monoclonal antibodies for the diagnosis, monitoring, imaging and therapy of human hematologic and solid tumor malignancies.

Immune response and immunoregulation: dissection of the basic human immune response and the roles of cytokines and other regulatory molecules and the demonstration and characterization of aberrant responses in neoplastic and immunologic disease.

Nutritional/ Hormonal Supplementation in Age Management and Immunologic Disease

Patents Issued: R.H. Keller and Dr. X. Wen: Allerg-ease (Patent Number 6,180,106) (2000) R.H. Keller, D.W. Kirchenbaum: ALL-Immune (Patent Number 6,262,019) (2002) R.H. Keller, PBS 119 a novel treatment for chronic viral infections (Patent Number 6,734,192) (2004)

Patents Pending: Keller R.H. A novel treatment For Viral Infections (CIP) 2005 Keller RH: An improved method for glutathione production in mammals 2007 Keller RH: A nutritional formula to promote weight loss in mammals Keller RH: A novel treatment for neurodegenerative diseases Keller RH: A nutritional formula to improve short term memory function

Books: Keller, R.H. After Thirty, Some Maintenance Is Required-A Practical Guide to Age Management

Book Chapters: Keller, R.H. and Tomasi, T.B.: Alpha-fetoprotein: A Potential Regulator of Immune Function. In Diseases of the Liver and Biliary Tract. Javitts, N.NIH, Bethesda, Maryland, pp. 119-134, 1977.

Keller, R.H., Calvinico, N.J., Fink, J.N., and Stevens, J.O.: Immunobiologic Aspects of Primate Hypersensitivity Pneumonitis. In Environmental Toxicology. Dungworth, D.L. (Ed), Academic Press, New York, pp.383-395, 1981.

Keller, R.H., Blake, D.G., Lyman, S. and Siebenlist, R.: The Immunobiology of Human Non-Hodgkin's' Lymphomas. In Clinical Cellular Immunology. Ludered, A. (ed). Humana Press, New York, pp. 213-246, 1982.

Patrick, C.W., Keller, R.H., and Horan, P.K.: Flow Cytometry, Cell Sorting and Hybridomas. American Society Clinical Pathology Press. St. Louis, MO, pp. 1-182, 1982.

Patrick, C.W., Parker, J., Keller, R.H., and Horan, P.K.: The Clinical Utility of Monoclonal Antibodies and Immunophenotyping. In Flow Cytometry and Cell Sorting in Hematologic Disease. American Society of American Pathologists Press. Chicago, IL pp. 1-191.

Calvinico, N.J., Fink, J.N., and Keller, R.H.: Hypersensitivity Pneumonitis. In The Immunology of the Lung. Bienenstock, J. (Ed), Academic Press, New York pp 365-366, 1984

Keller, R.H., Milson, T.J., Janicek, K.M., Patrick, L.C., Sohnle, P., and Patrick, C.W.: Clinical Utilization of the Technicon H-6000 Flow Cytochemical Flow System in Allergy Testing. In Proceedings of the 4th International Technicon Hematology Colloquium. Simson, E. (ed) Academic Press, New York, pp 179- 188, 1984.

Patrick, C.W., Horan, P.K, and Keller, R.H.: Immunophenotypic and Functional Analysis Using Laser Flow Cytometry: Clinical Utility. American Society of Clinical Pathology Press, Chicago, IL, 1985, pp. 1-168.

Patrick, C.W. and Keller, R.H.: Lymphocytes: Biochemistry, Physiology, Function and Morphology. In Principles of Hematology: Clinical and Laboratory Practice. R.L. Bick, (Ed) C.V. Mosby, St. Louis, MO in press.

Patrick, C.W. and Keller, R.H.: The Emerging Role of Laser Flow Cytometry and Monoclonal Antibodies in Clinical Medicine. In: Principles of Hematology: Clinical Laboratory Practice. R.L. Bick (Ed) C.V. Mosby, St. Louis, MO, in press.

Keller, R.H. and Patrick, C.W.: Characterization of the Human Myeloid Series by Monoclonal Antibodies. In Monoclonal Antibodies in Laboratory Medicine. Swartz, M. (Ed) Academic Press, New York, in press.

Patrick, C.W., McFadden, P.W., and Keller, R.H.: Immunophenotypic Analysis of Human Bone Marrow Employing Monoclonal Antibodies and Laser Flow Cytometry. In Proceedings of the Second International Conference on Technological Advances in Laboratory Hematology. Howen, B. (ed),Academic Press, 1985.

Keller, R.H., Janicek, K.M., and Patrick, C.W.: The Clinical Significance of Laser Flow Cytometry DNA Analysis. In Proceedings of the Second International Conference on Technological Advances in Laboratory Hematology. Howen, B. (Ed) Academic Press, New York, 1985.

Keller, R.H., Van Riel, F., Maislis, J., Lane, J.T., Reiter, W.M., Klimas, N.G, Fletcher, M.A.: Association of Histocompatability Class II Antigens wit the Chronic Fatigue Immune Dysfunction Syndrome. In Clinical Infectious Disease. University of Chicago, Chicago, IL, 1994:18 (Supp 1): S154-6.

Antioxidants and the skin, A Paradigm for aging. Keller, R.H and E Arrayove (in press) 2004.

Glutathione in Aging and Immunologic Disease. Loss of Gastrointestinal During Aging and Immunologic Disease Both Ed R. Wallace and Mechanisms of Aging Dove Press N Z, 2006

Original Research Contributions and Invited Reviews: Keller, R.H. and Tomasi, T.B.: Alpha-fetoprotein, E-Rosette Formation and Tumor Cell Growth. N Engl J Med 293(24): 1265-1266, 1975.

Tomasi, T.B., Dattwyler, R., Murgita, R. and Keller, R.H.: Immunosuppression By Alpha-fetoprotein. Trans Am Assoc Phys. 88:293-298, 1976.

Geubel, A.P., Keller, R.H., Summerkill, W.H.J., Dickson, E.R., Tomasi, T.B. and Shorter, R.G.: Lymphocyte Cytotoxicity and Inhibition Studied with Autologous Liver Cells: Observation in Chronic Acute Liver Disease and the Primary Biliary Cirrhosis Syndrome. Gasterenterol. 71:450-459, 1976.

Keller, R.H. and Clavanico, N.J., and Tomasi, T.B.: Immunosuppressive Properties of AFP: Role of Estrogens. In Onco Developmental Gene Expression. Fichman, W.H. and Sell, S. (eds) Academic Press, New York, p.278, 1976.

Keller, R.H. and Tomasi, T.B.: Synthesis of Alpha-fetoprotein by Murine Lymphoid Cells in Allogenic Reactions. J Exp Med 143:1120, 1976.

Banks, P., Keller, R.H., Li, V.Y. and White, E.B.: Malignant Lymphomas of Plasmablastic Identity: A Neoplasm with Both "Immunoblastic" and Plasma Cell Features. Am J Med 64:609-610, 1978.

Keller, R.H., Atwater, J.S., Martin, R.S. and Tomasi, T.B.: Ataxia Telangiectasia, Immunosuppression and AFP: Is There a Relationship? In Prevention of Neural- Tube Defects. Crandall, B. (ed) Academic Press, New York, pp.27-40, 1978.

Guirgis, H.A., Lynch, H.T., Keller, R.H., Tomasi, T.B., Vandervoorde, J., Brodky, F., Lynch, J., Rankin, L. and Malony, K.: Carcinoembryonic Antigen (CEA) and Alpha-fetoprotein (AFP) in Cancer-Prone Families: Communicable Implications. In Proceeding of the Third Annual Symposium on the Detection and Prevention of Cancer. Part I (2), 1987.

Keller, R.H., Dattwyler, R.J., Harrison, E. and Tomasi, T.B.: Alpha-fetoprotein in Human Lymphoproliferative Disease. J Lab Clin Immunol, 2:93-98, 1979.

Kaplan, H.J., Meredith, T.A., Aeberg, T.M. and Keller, R.H.: Intraocular Reticulum Cell Sarcoma (Histiocytic Lymphoma) in Richter's Syndrome: A Neoplasm of the Immune System. Arch Opthal 98:707-710, 1980.

Keller, R.H., Blake, B.G., Lyman, S. and Siebenlist, R.: ImmunoregulatoryAbnormalities in Chronic Lymphocytic Leukemia. J Lab Clin Immunol 6:201-208, 1981.

Choi, H. and Keller, R.H.: Co-existence of Chronic Lymphocytic Leukemia and Hodgkin's Disease. Cancer 48:48-55, 1981.

Kaplan, H.J., Aeberg, T.M. and Keller, R.H.: Etiology of Recurrent Clinical Uveitis. Ber Dtsch Ophthal Ges 78:159, 1981.

Kaplan, H.J. and Keller, R.H.: Recurrent Clinical Uveitis: Cell Surface Markers on Vitreous Lymphocytes. Arch Ophthal 100:585-592, 1982

Keller, R.H., Fink, J.N., Lyman, S. and Pederson, G.: Suppressor Cells in Asymptomatic Pigeon Breeders. J Clin Immunol 2:46-51, 1982.

Milson, T.J., Grief, D. and Keller, R.H.: The Variable Effect of Cryopreservation on Peripheral Blood Mononuclear Populations. J Clin Lab Immunol 7:205-218, 1982.

Keller, R.H., Calvanico, N.J. and Stevens, J.O.: Hypersensitivity Pneumonitis In Non-human Primates. In Studies on the Relationship of Immunoregulation and Disease Activity. J Immunol 128:116-123, 1982.

Keller, R.H.: Alpha-fetoprotein: Biologic and Clinical Potential. In Tumor Imaging: The Radioimmunochemical Detection of Cancer. Burchiel, S. and Rhodes, B. (eds) Mason Publishing, New York, pp. 179-188, 1982.

Patrick, C.W. and Keller, R.H.: New Techniques in the Diagnosis of Hematopoietic Malignancies: Monoclonal Antibodies, Flow Cytometry and Cell Sorting. Am Soc Clin Pathol Sp Topic Series 20(3)106-109, 1982.

Keller, R.H., Libnoch, J.A., Patrick, C.W., Blake, D.G., Choi, H. and Hanson, R.D.: Fc Gamma Bearing T Cells in Non-Hodgkin's Lymphomas. Diag Immunol 1:27-32, 1983.

Keller, R.H., Feldman, E. and Libnoch, J.A.: Immunoregulatory Abnormalities the Kindred of Waldenstrum's Macroglobulinemia Patients. Am J Hematol 14:15-22, 1983.

Keller, R.H. and Calvanico, N.J.: Suppressor Macro-molecules. Crit Rev Immunol 5(2): 149-199, 1984.

Fudenberg, H.H., Wilson, G.B., Keller, R.H., Metcalf, J.F., Pauling, E.E., Stuart, E.J. and Floyd, E.: Clinical Application of the Leukocyte Migration Inhibition Assay: New Methods for Determining Transfer Factor Potency and for Prediction of Clinical Response. In Proceedings of the IV International Conference on Transfer Factor. Academic Press, New York, pp. 293-310, 1984.

Patrick, C.W. and Keller, R.H.: A Simple Device for the Collection of Cells Sorted by Flow Cytometry: Preservation of Integrity and Viability. Cytometry 5(3):308-311, 1984.

Keller, R.H., Milson, T.J., Janicek, K.M. and Patrick, C.W.: Monoclonal Antibodies: Clinical Utility and the Misunderstood Epitope. Lab Med 15(12):785-802, 1984.

Keller, R.H., Swartz, S.J., Leven, S., Bar Sella, S. and Fink, J.N.: Immunoregulation in Hypersensitivity Pneumonitis: Phenotypic and Functional Studies of Bronchoalveolar Lavage Lymphocytes. Am Rev Resp Dis 130:766- 771, 1984.

Patrick, C.W., Swartz, S.J., Harrison, K.A. and Keller, R.H.: Collection and Preparation of Hemopoietic Cells for Cell Marker Analysis. Lab Med 15(10): 659-665, 1984.

Patrick, C.W., Milson, T.J., McFadden, P.W. and Keller, R.H.: Flow Cytometry and Cell Sorting. Lab Med 15(11):740-745, 1984.

Wilson, G.B., Fudenberg, H.H. and Keller, R.H.: Guidelines for Immunotherapy of Antigen Specific Defects with Transfer Factor. J Clin Lab Immunol 13:51-58, 1984.

Baumann, M.A., Libnoch, J.A., Patrick, C.W., Choi, H. and Keller, R.H.: Prolonged Survival in Richter's Syndrome with Subsequent Re-emergence of Chronic Lymphocytic Leukemia: A Case Report Including Serial Cell Surface Phenotype Analysis. Am J Hematol 20:67-72, 1985.

Marti, G.E., Patrick, C.W., Muirhead, K., Magruder, L., Vail, M., Schuette, W., Keller, R.H., Horan, P.K. and Gralnick, H.R.: Normal Blood Density Gradient Lymphocyte Subset Analysis: In an Inter-Laboratory Flow Cytometric Comparison of 85 Normal Adults. Am J Hematol 20:41-52, 1985.

Milson, T.J., Patrick, C.W., Sohnle, P.G., Patrick, L.C. and Keller, R.H.: Flow Cytochemical Analysis of Atopic Reactions. Diag Immunol 3:182-186, 1986.

Milson, T.J., Patrick, C.W., Torke, N.J. and Keller, R.H.: Holding Media for Cell Surface Phenotyping Analysis, J Immunol Methods 87: 155-159, 186.

Baumann, M.A., Milson, T.J., Patrick, C.W., Libnoch, J.A. and Keller, R.H.: Immunoregulatory Abnormalities in Myelodysplastic Disorders. Am K Hematol 22:79-86, 1986

Hansen, R.M, Lerner, N., Abrams, R.A., Patrick, C.W., Malik, M.I. and Keller, R.H.: Chronic Lymphocytic Leukemia with Pure Red Cell Aplasia: Laboratory Demonstration of Persistent Leukemia in Spite of Apparent Complete Clinical Remission. Am J Hematol 22:79-86, 1986.

Baumann, M.A., Keller, McFadden, P.W., Libnoch, J.A and Patrick, C.W.: Myeloid Cell Surface Phenotype in Myelodysplasia: Evidence for Abnormal Persistence of an Early Myeloid Differentiation Antigen. Am J Hematol 23:22-26, 1986.

Baumann, M.A., Milson, T.J., Patrick, C.W., Libnoch, J.A. and Keller, R.H.: Correlation of Numbers of Natural Killer Cells with Clinical Course in Large Cell Lymphoma. Cancer 57:2309-2312, 1986.

Patrick, C.W., Ash, R., Libnoch, J.A. and Keller, R.H.: Clinical Cytometry and Immunophenotyping: I. Flow Cytometric Analysis of Normal Peripheral Blood and Bone Marrow. Path Immunopathol Res 6:64-76, 1987.

Patrick, C.W., Libnoch, J.A., Kallas, G.A. and Keller, R.H.: Sequential Immunophenotypic Studies in Chronic Lymphocytic Leukemia: UCLA Molecular Biology Symposium. Chronic Lymphocytic Leukemia: Recent Progress-Future Directions. R. Gale and K. Rai (eds) Alan R. Liss, New York, 59, 1987.

Keller, R.H., Libnoch, J.A., Kallas, G.A., and Patrick, C.W.: Sequential Evaluation of T Cell Subsets in B-CLL. UCLA Molecular Biology Symposium Chronic Lymphocytic Leukemia: Recent Progress-Future Directions. R. Galeand K. Rai (eds) Alan R. Liss, New York, 59, 1987.

Fudenberg, H.H, Whitten, H.D., Galbraith, G.M.P., Goust, J.M., Patrick, C.W. and Keller, R.H.: Deficiency of 'Interactive' T Cells in Individuals with Recurrent Infection: Effect of DLE-TF Therapy. Am J Med. In Press, 1994.

Keller, R.H., Van Reil, F., Maislis, J., Lane, J.T., Reiter, W.M., Klimas, N.G. and Fletcher, M.A.: Association of Histocompatability Class II Antigens with the Chronic Fatigue Immune Dysfunction Syndrome. In Clin Inf Disease 1 8(Supp 1): S154-156, 1994.

Papers Submitted, In review and/or Revision Patrick, C.W. and Keller, R.H.: A Comparative Study of Anticoagulants in Cell Surface Maker Phenotyping and Functional Analysis. Am J Clin Pathol.

Keller, R.H., Choi, H., Libnoch, J.A. and Patrick, C.W.: A Natural Murine Model of Non-Hodgkin's Lymphoma. J Immunol (in revision).

Choi, H., Libnoch, J.A., Aimargo, U., Heckman, M. and Keller, R.H.: Castelman's Tumor: Well Differentiated Lymphocytic Lymphoma and Large Cell Lymphoma in a Single Patient. Human Pathol (in revision).

Keller R.H., Wen K., and Kirchenbaum G. ALL-ergese a TCM blend of standardized herbs for the treatment of allergies. (in revision)

Adult Growth Hormone Deficiency: A Correlate of Immune Overactivity (in preparation)

ABSTRACTS: Asterisks (*) denote those papers selected for presentation at national or international meetings.


 * Keller, R.H., Dattwyler, R.J., Harrison, E. and Tomasi, T.B.: Alpha- fetoprotein in Human Lymphoproliferative Disease. Blood 46(4):1035, 1975.


 * Guebel, A.P., Keller, R.H., Summerskill, W.H.J., Tomasi, T.B. and Shorter, R.G.: Cytotoxicity of Autologous and Normal Lymphocytes Against Isolated Liver Cells in Patients with Primary Biliary Cirrhosis. Gastroenterol 68:104, 1975.


 * Keller, R.H., Summerskill, W.H.J., Guebel, A.P., Shorter, R.G., and Tomasi, T.B.: Alpha-fetoprotein and Suppression of Cell Mediated Immunity in Chronic Acute Liver Disease (CALD). Gastroenterol 70:A-43:901, 1976.


 * Keller, R.H, Guirgis, H., Lynch, H. and Tomasi, T.B.: Alpha-fetoprotein (AFP) in Cancer Prone Families. Clin Res 24:331, 1976.


 * Keller, R.H., Burritt, M.F., Thompson, R.L. and Tomasi, T.B.: Alpha- fetoprotein (AFP): Synthesis in Allogeneic Reactions. Clin Res 24:447, 1976.


 * Keller, R.H., Burritt, M.F. and Tomasi, T.B.: Alpha-fetoprotein (AFP) Synthesis in Allogeneic Reactions. Eleventh Leukocyte Culture Conference, Tucson, AZ, September 1976.


 * Guirgis, H.A., Lynch, H.T., Keller, R.H., Tomasi, T.B., Vandervoorde, J., Lynch, J., Rankin, L., Maoney, K. and Harris, R.: Carcinoembryonic Antigen (CEA) and Alpha-fetoprotein (AFP) in Cancer Prone Families. In Proceedings of the Scientific Session of the Third International Symposium on the Detection and Prevention, 1976.


 * Vogten, A.J.M., Shorter, R.G., Summerskill, W.M.J., Keller, R.H. and Tomasi, T.B.: Cell Mediated Cytotoxicity Against Human Liver Lipoprotein in Liver Disease. Gastroenterol 71:A-41:934, 1976.


 * Keller, R.H. and Tomasi, T.B.: AFP: A Potential Regulator of Immune Function. Second International Conference on Disease of the Liver. Bethesda, MA, March 1977.

Keller, R.H., Blake, D.G., Lyman, S., Libnoch, J.A. and Fabiance, M.: Suppressor Cells in Asymptomatic Chronic Lymphocytic Leukemia. Clin Res 27:298, 1979.

Keller, R.H., Blake, D.G., Lyman, S. and Siebenlist, R.: Altered Immunoregulation in Chronic Lymphocytic Leukemia. Blood 54:97A, 1979.

Blake, D.G., Libnoch, J.A., Lyman, S. and Keller, R.H.: Altered Immunologic Reactivity in Myelodysplastic Disorders. Blood, 54:97A, 1979.


 * Miller, P.P, Jordan, R.E. and Keller, R.H.: Suppression of Human Lymphocyte Response by Circulating Immune Complexes. Clin Res 28: 351, 1980.


 * Keller, R.H., Fink, N.J., Lyman, S. and Pederson, G.: Altered Immunoregulation in Hypersensitivity Pneumonitis. Clin Res 28:102, 1980.


 * Keller, R.H., Lyman, S. and Siebenlist, R.: The Influence of Human Mononuclear Cell Histamine Production on T Cell Immunoregulation. Clin Res 28:230, 1980.


 * Keller, R.H., Lyman, S. and Siebenlist, R.: Histamine in the Immune Response. 4th World Congress of Immunology, Paris, France. July 1980.


 * Kaplan, H.J., Asberg, T.M. and Keller, R.H.: Lymphocyte Subset in Clinical Uveitis. Abs Assoc Res Vision Opthal p. 33, 1980.


 * Siebenlist, R., Calvanico, N.J., Stevens, J.O. and Keller, R.H.: Immunoregulation in Hypersensitivity Pneumonitis. Fourth Midwest Autumn Immunology Conference, Chicago, IL, 1980.


 * Lyman, S., Patrick, C.W. and Keller, R.H.: Non-Hodgkin's Lymphoma in the Mouse: A Naturally Occurring Murine Model of NHL. Fourth Midwest Autumn Immunology Conference, Chicago, IL, 1980.


 * Young, D.G., Hussey, C.V., Keller, R.H. and Pisciotta, A.V.: Eradication of Acquired Factor VII Inhibitor in Hodgkin's Disease Following Chemotherapy. Am Fed Clin Res 28(4):731, 1980.


 * Keller, R.H., Patrick, C.W., Swartz, S.J., Libnoch, J.A. and Jordan, R.E.: FlowCytometry as an Adjunct in the Diagnosis and Staging of Lymphoproliferative Disease. IX International Conference on Analytical Cytology. Schloss Elmau, Germany, 1980.


 * Wilson, R.J., Greiff, D. and Keller, R.H.: Cryopreservation of Non- specific T Cell Suppressor Cells. Cryobiol 17:597, 1980.


 * Pontzer, C. and Keller, R.H.: Rabbit Peripheral Blood T Cell Separation. Fed Am Soc Exp Biol, 1980.


 * Keller, R.H., Calvanico, N.J. and Stevens, J.O.: Immunoregulation in Pigeon Breeders Disease. Clin Res 29:370, 1981.


 * Keller, R.H., Kirchner, P., Lyman, S., Siebenlist, R., Choi, H. and Patrick, C.W.: Immunoregulatory T Cells in Non-Hodgkin's Lymphomas. Blood 58:313, 1981.


 * Keller, R.H., Lyman, S., Choi, H. and Patrick, C.W.: A Natural Model of Non-Hodgkin's Lymphoma. Blood 58:524, 1981.


 * Lauer, S., Casper, J., Keller, R.H., Kirchner, P. and Camitta, B.: The Use of Counterflow Centrifugation-Elutriation for the Separation of Bone Marrow Lymphoid Cells in Children with Acute Lymphocytic Leukemia (ALL) and Metastatic Solid Tumors. Blood 58:133, 1981.


 * Keller, R.H., Choi, H. and Patrick, C.W.: Nodular Non-Hodgkin's Lymphoma in the Mouse. Blood 60:114A, 1982.


 * Keller, R.H., Lyons, M., Troy, J. and Jordan, R.E.: Peripheral Blood Aneuploidy in Mycosis Fungoides and Pre-mycotic Lesions. Blood 60:146A, 1982.


 * Keller, R.H., Swartz, S.J., Lyons, M., Troy, J. and Jordan, R.E.: Peripheral Blood Involvement in Skin-limited T Cell Malignancy. Am Fed Clin Res 31:568, 1983.


 * Geoghegan, W.D., Jordan, R.E. and Keller, R.H.: Non-Langerhans Cells in the Keratinocyte Band in Culture Expressing HLA-DR. Invest Derm Am Fed Clin Res 31:568, 1983.


 * Keller, R.H., Swartz, S.J., Patrick, C.W. and Kaplan, H.J.: Intraocular Lymphoma: A Possible Systemic Disease. Am Fed Clin Res 31:315, 1983.


 * Patrick, C.W., Libnoch, J.A., Choi, H. and Keller, R.H.: Flow Cytometric Peripheral Blood Cell Surface Analysis as a Predictor of Richter's Syndrome (RS) in Chronic Lymphocytic Leukemia. Blood 62:756, 1983.


 * Patrick, C.W., Swartz, S.J. and Keller, R.H.: A Comparative Study of Heparin and Potassium EDTA as Anticoagulants for Cell Surface Marker and Immunologic Functional Analysis. Am J Clin Pathol, 1983.


 * Keller, R.H., Swartz, S.J., Patrick, C.W., Steven, G. and Torke, N.J.: Regression of Natural Murine Non-Hodgkin's Lymphoma Following Immunotherapy with Immunoregulatory Cell Types. Blood 62:756, 1983.


 * Keller, R.H., Wagner, D. and Patrick, C.W.: Sequential T Cell Phenotypic and Functional Changes During a Comparative Study of Rhinovirus Infection in Patients with the Acquired Immune Deficiency Syndrome (AIDS). Blood 62:352, 1983.


 * Keller, R.H., Swartz, S.J. and Patrick, C.W.: Metachromatic Granules in Human T8 (CD8) Bearing Lymphocytes. Fifth World Congress of Immunology. Tokyo, Japan. July 1983.

Libnoch, J.A., Patrick, C.W., Griffin, J. and Keller, R.H.: Flow Cytometric Cell Surface Analysis as a Predictor of Leukemic Transformation in the Myeo-dyplastic Syndrome (MDS). Blood 62:610A, 1983.


 * Calvanico, N.J., Pontzer, C. and Keller, R.H.: Regulation of Aerosol Induced Pulmonary Inflammation in Rabbits. XII Congress of the European Academy of Allergy and Clinical Immunology, Rome, Italy, 1983.


 * Patrick, C.W., Swartz, S.J., McFadden, P.W., Wallace, A. and Keller, R.H.: A Comparative Study of Manual and Flow Cytometry Cell Surface Marker Analysis. Soc Analytical Cytology, Sea Island, Georgia, 1983.


 * Keller, R.H., Swartz, S.J., Troy, J., Patrick, C.W. and Jordan, R.E.: Peripheral Blood Involvement in Skin Limited T Cell Malignancy. Soc Analytical Cytology, Sea Island, Georgia, 1983.


 * Keller, R.H., Swartz, S.J., Leven, S. and Bar Sella, S.: Immunoregulation in Hypersensitivity Pneumonitis: Phenotypic and Functional Studies of Bronchoalveolar Lavage Lymphocytes. Am Acd Allergy 130:766-771, 1984 Vitro Immunoglobulin Synthesis in Chronic Lymphocytic Leukemia. Blood 66:202, 1985.


 * Keller, R.H., Patrick, L.C. and Patrick, C.W.: Isoprinosine Augments In Vitro Immunoglobulin Synthesis in Chronic Lymphocytic Leukemia (B-CLL). International Symposium on Recent Approaches to Chronic Lymphoproliferative Disease, Prague, Czechoslovakia, September 1985.


 * Keller, R.H., Milson, T.J. and Patrick, C.W.: The Relationship of Larger Lymphoid Elements, Clonally Restricted DNA Cell Cycle Analysis and Rai Staging in Chronic Lymphocytic Leukemia (B-CLL). International Symposium on Recent Approaches to Chronic Lymphoproliferative Disease, Prague, Czechoslovakia, September 1985.


 * Patrick, C.W., Libnoch, J.A. and Keller, R.H.: Immunophenotypic Dissection Of Chronic Lymphocytic Leukemia. International Symposium on Recent Approaches to Chronic Lymphoproliferative Disease, Prague, Czechoslovakia, September 1985.


 * Keller, R.H., Libnoch, J.A., Patrick, L.C. and Patrick, C.W.: In Vitro Improvement of Cellular and Humoral Immune Response by Isoprinosine in B-CLL. XXI Congress of the International Society of Haematology, Sydney, Australia, May 1986.


 * Patrick, C.W., Libnoch, J.A. and Keller, R.H.: Prolymphocytic Leukemia of B Cells is a Distinct Biologic Stage in B Cell Maturation. XXI Congress of The International Society of Haematology, Sydney, Australia, May 1986.


 * Patrick, C.W., Libnoch, J.A. and Keller, R.H.: Sequential Changes in the Expression of Lymphoid Surface Membrane Receptors in Chronic B Cell Lymphoproliferative Disease. XXI Congress of the International Society of Haematology, Sydney, Australia, May 1986.


 * Patrick, C.W., Libnoch, J.A. and Keller, R.H.: Clinical Utility of Dual Immunofluorescence Assay of Monoclonal Antibodies TQ1 and B4 (CD19) on Circulating B Cells in Chronic Lymphocytic Leukemia (B-CLL). Sixth International Congress of Immunology, Toronto, Canada, July 1986.


 * Keller, R.H., Milson, T.J., Ellingboe, K.M. and Patrick, C.W.: Sequential Clinical, Immunoregulatory, Phenotypic and Functional Changes in Patients with AIDS and ARC treated with Isoprinosine. XXI Congress of the International Society of Haematology, Sydney, Australia, May 1986.


 * Keller, R.H., Milson, T.J., Ellingboe, K.M. and Patrick, C.W.: Sequential Clinical, Immunoregulatory, Phenotypic and Functional Changes in Patients with AIDS and ARC treated with Isoprinosine. International Conference on the Acquired Immunodeficiency Syndrome, Paris, France, June 1986.


 * Keller, R.H., Libnoch, J.A. and Patrick, C.W.: T Cell Alterations in B-CLL: Sequential Changes in CD4 and CD8 Bearing Cells and in T Cell Immunoregulation. UCLA Symposium on Molecular and Cell Biology, Silverado, California, December 1986.


 * Patrick, C.W., Libnoch, J.A., Kallas, G.A. and Keller, R.H.: Sequential Immunophenotypic Studies in Chronic Lymphocytic Leukemia. UCLA Symposium on Molecular and Cell Biology, Silverado, California, December 1986.


 * Reiter, W.M., Berger, D.S., Vorce, S., Cimoch, P.J., Vargas, A. and Keller, R.H.: Combination Zidovudine and Didanosine Therapy for Patients Remaining Persistently HIV P24 Antigen-Positive Despite Zidovudine Monotherapy. VIII International AIDS Conference, Amsterdam, Netherlands, 1992.


 * Reiter, W.M., Keller, R.H., Cimoch, P.J. and Forgione, A.: A Rapid Quantitative Flow Cytometry Assay to Evaluate CD4 + - Lymphocyte Activation Potential in Patients with HIV-1 Infection. VIII International AIDS Conference, Amsterdam, Netherlands, 1992.


 * Cimoch, P.J., Reiter, W.M., Vorce, D., Cassarella, S.K., Thompson, B. and Keller, R.H.: The Occurrence of Cytomegalovirus (CMV) Viruria in Late- Stage HIV-1 Infection and its Association with CMV Organ Involvement. VIII International AIDS Conference, Amsterdam, Netherlands, 1992.


 * Reiter, W.M., Beach, R.S., Vorce, D., Cimoch, P.J., Vargas, A., Thompson, B. and Keller, R.H.: Longitudinal Analysis the Effect of Anti-retroviral Monotherapy on CD4+ Lymphocyte Percentage. VIII International AIDS Conference, Amsterdam, Netherlands, 1992.


 * Keller, R.H., Van Reil, F., Maislis, J., Lane, J.T., Reiter, W.M., Klimas, N.G. and Fletcher, M.A.: Correlation of DR4 and DQ1 with Immunologic Defects in the Chronic Fatigue Syndrome. First International Chronic Fatigue Syndrome Research Conference, Albany, New York, October 1992.


 * Keller, R.H., Reiter, W.M., Lane, J.T., Klimas, N.G., Vargas, A. and Maislis, J.A.: Treatment of Late-Stage AIDS Patients with Combined Monthly Anti-HIV Hyperimmunoglobulins and Haplotype-matched Peripheral Blood Lymphocytes. XI International Conference on AIDS, Berlin, 1993.

Reiter, W.M., Cimoch, P.J., Vorce, D.E., Keller, R.H., Berger, D. and Ping, A.:Eighteen Month Longitudinal Analysis of the Effect of Zidovine MonotherapyCompared to Combination Antiretroviral Therapy on HIV1 Disease Progression. IX International Conference on AIDS, Berlin 1993.


 * Reiter, W.M., Vorce, D.E., Cimoch, P.J., Keller, R.H., Berger, D.S., and Ping, A.C.: Cytotoxic CD8+ Lymphocyte Response to HIV-1 Infection Correlated with Longitudinal Analysis of CD4+ Lymphocyte Percentage. IX International Conference on AIDS, Berlin, 1993

Berger, D.S., Reiter, W.M., Vorce, D.E., Cimoch, P.J., Keller, R.H. and Ping, A.C.: Prevalence of Red Blood Cell Magnesium Deficiency in HIV-1 Infected Patients and its Association with Fatigue and Myalgia. IX International Conference on AIDS, Berlin, 1993.

Reiter, W.M., Tomaka, F., Keller, R.H., Cimoch, P.J., Vargas, A. and Vorce, D.E.: Unrecognized Moderate to Advanced Immunodeficiency in "HIV-Aware" Asymptomatic, Untreated Person with HIV-1 Infection. IX International Conference on AIDS, Berlin, 1993.


 * Gomatos, P.J., Keller, R.H., Reiter, W.M., Lane, J.T., Cimoch, P.J., Vorce, D.E., Gianetti, B.L. and Uribe, M.R.: Haplotype-Matched Peripheral Blood Mononuclear Cell (PBMC) Transfusions in Patients with Late-Stage AIDS. X International Conference on AIDS, Yokohama, Japan, 1994.


 * Cimoch, P.J., Loss, S.D., Houghton, R.A., Reiter, W.M., Keller, R.H., Vorce, D.E., Nemecheck, P.M., Berger, D.S. and Tomaka, F.L.: Antibody Response to Pneumococcal Vaccination in HIV-1 Infected Patients. X International Conference on AIDS, Yokohama, Japan, 1994.


 * Tomaka, F.L., Cimoch, P.J., Reiter, W.M., Keller, R.H., Berger, D.S., Piperato, J.R., Nemecheck, P.M., Loss, S.D. and Houghton, R.A.: Prevalence of Nutritional Deficiencies in Patients with HIV-1 Infection. X International Conference on AIDS, Yokohama, Japan, 1994.


 * Keller, R.H., Helder, L.M., Piperato, J.P., Klimas, N.G., Reiter, W.M., Fletcher, M.A., Vorce, D.E. and Pittibone, H.: Symptomatic Improvement Associated with Down Regulation of Immune Hyper Reactivity by Calcium Channel Blockade in CFIDs. American Association for Chronic Fatigue Syndrome Research Conference, Ft Lauderdale, Florida, 1994.


 * Keller, R.H., Nolan, R.P. and Patrick, L.C.: Natural Human Interferon ( (Alpha Leukoferon) Therapy in a Cohort of Hemophiliacs Co-infected with . HIV and Hepatitis C. Fourth Conference on Retroviruses and Opportunistic Infections,Washington, DC, 1997.


 * Patrick, C.W. and Keller, R.H.: Patient Screening for Myelodysplasia in Long- Term HIV+ Individuals. Conference on Clinical Laboratory Testing in HIV, Atlanta, GA, 1998.


 * Patrick, C.W., DeLeon, M., A. Leon, and Keller, R.H.: Measurement of glutathione (GSH) as Indicator of Immune Status. Conference on Clinical Laboratory Testing in HIV, Atlanta, GA 1998.


 * Kushch, A. and Keller, R.H.: Neuropsychological Correlates of Adjunct Therapy with a Nutritional/Vitamin Supplement in a Medical Patient Sample. National Academy of Neuropsychology, ** Orlando, FL, November 2000.

Keller, R.H.:PBS 119 Abstract "Clinical Results of PBS 119 in Eight Patients for Two Years" Submitted to the 12th Conference on Retroviruses & Opportunistic Infections (CROI), 2005

Keller, R.H.: PBS 119 Abstract "In Vitro Analysis of PBS 119 Against HIV Viral Activity in Lab Adapted and HAART Resistant Strains of HIV" Submitted to the 12th Conference on Retroviruses & Opportunistic Infections (CROI), 2005


 * Keller, R.H, Miller D glutathione and DHA deficiency in HIV/AIDS : Correction with Immune Vitality 16th International AIDS congress Toronto Canada 8/2006


 * Keller, R.H And Nyugen V. : PBS 119 A Novel Host - Viral Interaction inhibitor 16th International AIDS Congress Toronto Canada 8/2006

Patent of the product

United States Patent 	6,262,019 Keller,  et al. 	July 17, 2001 ________________________________________ Method of treatment of glutathione deficient mammals Abstract Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intracellulary either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels. The disclosure is also of a unique combination of nutritional supplements including n-acetyl cysteine, vitamin C, l-glucosamine, n-acetyl d-glucosamine, quercitin, sylimarin, Alpha lipoic acid and high protein, low fat whey that are combined to support various bodily systems involved in glutathione synthesis, reutilization and storage; all intended to elevate glutathione concentration in the mammalian cell. ________________________________________ Inventors: 	Keller; Robert H (Weston, FL), Kirshenbaum; David W (Weston, FL) Assignee:	Vit-Immune, L. C. (Hollywood, FL) Appl. No.: 	09/302,217 Filed: 	April 29, 1999 ________________________________________ Current U.S. Class:	514/5.5 ; 424/49; 424/535; 424/54; 424/655; 514/1.4; 514/1.5; 514/15.1; 514/16.4; 514/16.6; 514/17.7; 514/18.9; 514/19.2; 514/19.3; 514/21.9; 514/23; 514/251; 514/276; 514/3.8; 514/4.3; 514/6.9; 530/365; 530/833 Current International Class: 	A23L 1/302 (20060101); A23L 1/305 (20060101); A23L 1/30 (20060101); A61K 31/70 (20060101); A61K 31/185 (20060101); A61K 31/197 (20060101); A61K 31/375 (20060101); A01N 037/18 ; A61K 038/02 Field of Search: 	514/2,7,12,23,21,251,276 424/54,49,535,655 530/365,833 ________________________________________ References Cited [Referenced By] ________________________________________ U.S. Patent Documents 4256760 March 1981	Los 4277496 July 1981	Los 4292403 September 1981	Duermeyer 5290571 March 1994	Bounous et al. 5456924 October 1995	Bounous et al. 5696109 December 1997	Malfroy-Camine et al.

Other References

PROMT on STN, Information Access Company, 1998: 1310, BioDynamax Supplement--Ultra Antioxidants Tablets, Product Alert (Dec. 22, 1997) ISSN: 0740-3801.*. "Screening of Potential Chemopreventive Agents Using Biochemical Markets of Carcinogenesis" by Sheela Sharma, Jill D. Stutzman, Gary J. Kelloff and Vernon E. Steele, Cancer Resreach 54, 5848-5855, Nov. 15, 1994. . Low Blood Glutathione Levels in Healthy Aging Adults, pp 720-725, Calvin A. Long, et al.. a-Lipoic Acid: Biological Effects and Clinical Implications, pp 177-183, Trent W. Nichols, Jr. M.D.. Glutathione: Systemic Protectant Against Oxidative and Free Radical Damage, pp 155-171, 173-176, Parris M. Kidd, Ph.D.. Importance And Regulation of Hepatic Glutathione, pp 251-266, Laurie D. Deleve, M.D., Ph.D. et al.. Probiotics in Human Medicine, pp 439-442, R. Fuller. . Aids Wasting Syndrome as an Entero--Metabolic Disorder: The Gut Hypothesis, pp 40-45, 47-43, Mitchell Kaminski, Jr., M.D., et al.. The Effects of L-Glutamine, N-Acetyl-D-Glucosamine, Gamma-Linolenic Acid and Gamma-Oryzanol on Intestinal Permeability..

Primary Examiner: Carlson; Karen Cochrane Assistant Examiner: Tu; Stephen Attorney, Agent or Firm: Pitney, Hardin, Kipp & Szuch, LLP

Dr. John C. Nelson, 159th President of the American Medical Association about Max GXL:

“This product, in my opinion, represents the single most important breakthrough in health that I will witness in my life time. I believe it will revolutionize, change, and transform the practice of medicine world-wide and make Dr Robert Keller more famous than Jonas Salk who created the polio vaccine.”

Magnesium deficiency (agriculture)
Please, explain, what means this edit. It is highly implausible that a very experienced user is not familiar with well known things about page moves and maintaining edit histories. Incnis Mrsi (talk) 11:06, 8 March 2011 (UTC)
 * You may find it "highly implausable" that a highly experienced editor did not know there was a reason not to move a page by copy-and-paste, but this is the first I've heard of a need to preserve a sacrosanct edit history for copyright purposes. You'd think that with all the destruction of contested articles, that are eventually again started in another form or by another name (with no attribution to previous versions), and then kept, that somebody would have mentioned this potential alligator in the swamp. ;) Never have I seen a mention of it in the RfD wars. Nor did I know that non-admins can move a page using page-move. So, I learned two things. Next time, I'll do it correctly. Thanks for the lesson. S  B Harris 18:11, 8 March 2011 (UTC)

Green Laser
Hi. Can you please tell me if any green laser pointer is powerful enough to lit up matches. Thanks. Kindly reply on my talkpage. Jon Ascton   (talk)  16:09, 11 March 2011 (UTC)
 * How would I know without more details? If it's 200 mW or more, and pointer-style, thus poorly IR filtered, odds are good. Also, that it will cause eye damage instantly if you screw with it. S  B Harris 17:50, 11 March 2011 (UTC)

BLP, ethnicity, gender
Wikipedia talk:Biographies of living persons

Some say source requirements for ethnicity and gender of WP:EGRS don't apply to WP:BLP living persons, simply because the two words aren't in the policy. (Apparently, they think it should only apply to dead people.) I see that you have participated on this topic at the Village Pump.

They also are trying to remove the notability, relevance, and self-identification criteria at WT:EGRS, but that's another fight for another day, I'm simply too busy to watch two fronts at the same time.

We're on the 6th day. Traditionally, these polls go for 7; unless there's no obvious consensus, when we go for an additional 7 days. --William Allen Simpson (talk) 16:57, 12 March 2011 (UTC)

Discussion at Iodine
Please contribute to the discussion at: Talk:Iodine Thanks 14:33, 15 March 2011 (UTC)

Sockpuppetry case
Your name has been mentioned in connection with a sockpuppetry case. Please refer to Sockpuppet investigations/Sbharris for evidence. Please make sure you make yourself familiar with the guide to responding to cases before editing the evidence page. SummerPhD (talk) 02:04, 22 March 2011 (UTC)

Talk:Fluorine
Hi Sbharris, Well I do know about essential uses of things like BFCs, but that is as much as I'll say. They (BCF) work by starving the fire of "oxygen": so in an aircraft the engine housing is flooded with BCF in the case of a fire. I would certainly not recommending flooding the cabin of a passenger aircraft with BFCs; that certainly would produce hypoxia and people would die. Same with nuclear and non-nuclear submarines, a compartment can be flooded with BCF and people can remain in it provided that they are wearing BA sets (air or oxygen) but I would not like to do it myself. However, "problems" can occur when the captain decides to test the fire supression system and discharges half a tonne of BCF just to put a "tick in the box" - I tested the system and it worked (signed) "captain", today's-date. I suspect that you were "letting off steam", I'm not sure that your comments were related to awarding or not-awarding the article GA-status. Pyrotec (talk) 18:12, 22 March 2011 (UTC)
 * You don't know the first thing about BFCs. If they worked as you say, argon could replace them (and argon is actually used in many fire suppression systems). BFCs work additionally by decomposing in a flame to produce bromine atoms which act as free radical terminators to stop a fire. It's quite possible to stand in a room with 20% BFC, breathing normally and comfortably, and yet be unable to light a match. That used to be used as a demo in the old days of TV when there was the strange idea of better living through chemistry. It's quite possible some aircraft use amounts of fire surppression BFC that would be suffocating, but that's not REQUIRED, and is not the issue. S  B Harris 18:18, 22 March 2011 (UTC)

Reference
Do you have a ref for the addition to scabies? Thanks Doc James  (talk · contribs · email) 04:36, 4 April 2011 (UTC)

 "The pathognomonic signs of scabies are burrows, erythematous papules, and generalized pruritus (also on non-infested skin) with nocturnal predominance.3 Reddish to brownish extremely pruritic nodules of 2 to 20 mm in diameter may be also present on the genitalia (more commonly in males than in females), buttocks, groin, and axillary regions. Patients usually have secondary papules, pustules, vesicles, and excoriations. Every patient with intense pruritus should be suspected of having scabies, but especially if a family member reports similar symptoms.3 A diagnosis can be made clinically if a burrow is detected at a typical predilection site and if the lesion itches severely. In this case, even a single burrow is pathognomonic.2"

Sorry, that's the nearest I can come to what I remember. Personally, it's difficult for me to tell a burrow from a mosquito bite (unless it's in a place mosquitos are not likely to get to). But I've always found linear closely-spaced collections of "mosquito-bites" on thin, hairless skin, along with a terrible itch, pathognomonic. Quite literally, nothing else does that. S B Harris 06:39, 4 April 2011 (UTC)

Individual element nuclide stability charts
Well I tried to communicate, but you have more important interests. So will see you around. Cheers.WFPM (talk) 02:44, 11 April 2011 (UTC) But Proofreading of the Femto data is not going to improve the understanding of it. And there were also errors in the CRC data.

I'm trying to get some help in posting a element nuclide stability chart about the data Femto has posted about the isotopes of lead, which, of course, includes the presently considered heaviest stable isotope EE82Pb208. Personally, I think people should pay more attention to the potential stability of an isotope of 86Rn Radon, because it should be comparable to 54Xe Xenon in structural stability (with EE54Xe136 being stable with 28 extra neutrons, But a stable EE86Rn isotope might be hard to detect.WFPM (talk) 22:29, 12 May 2011 (UTC)

In my contributions file I have an element stability profile chart (and discussion) prepared that I would like to import to my contribution to Talk:Isotopes of lead. Could you please look at it and see if you could help me get it imported? its address is [] I would appreciate it.WFPM (talk) 20:39, 15 May 2011 (UTC)

With all you know about chemistry and physics, you must see that we have to pin down the so called reliable sources of this data to the maximum up to date accuracy of determining and reporting the pertinent isotope halflife and other data. And a charting tool, such as I,m proposing, is obviously a way to call attention to apparent discrepancies, and why Berkeley, or ORNL, or LANL, doesn't use it I don't know but I've called it to their attention. And to tell me that I can't discuss it in Wikipedia due to some "OR" log second time interval calculation is carrying things beyond reasonability and not helping with the getting and organizing of the needed additional information. I guess their argument must be that they report the information that they are given, and are not allowed to speculate. But progress in Science is about movimg the state of the knowledge and art of things and I'm alive due to their accomplishments along those lines. But I don't have the time and/or patience to wait much longer until someone gets an idea to do something about it. So there!WFPM (talk) 02:18, 2 December 2011 (UTC)

Invitation to take part in a pilot study
I am a Wikipedian, who is studying the phenomenon on Wikipedia. I need your help to conduct my research on about understanding "Motivation of Wikipedia contributors." I would like to invite you to a short survey. Please give me your valuable time, which estimates only '''5 minutes’’’. cooldenny (talk) 18:27, 14 April 2011 (UTC)

Wyatt Earp reassessment
An article that you have been involved in editing, Wyatt Earp has been nominated for a good article reassessment. If you are interested in the discussion, please participate by adding your comments good article reassessment page. If concerns are not addressed during the review period, the good article status will be removed from the article.

Proposal 4, Proposal 42
Please check your Support comment at WT:V. You may have mistakenly put it in Proposal 42 instead of Proposal 4. 75.47.133.9 (talk) 16:34, 21 April 2011 (UTC)

You're not smart
but it's cool bro —Preceding unsigned comment added by 74.109.118.163 (talk) 18:43, 25 April 2011 (UTC)
 * Indeed. Most people, including myself, get along perfectly well in life and on WP, without it. S  B Harris 19:53, 1 May 2011 (UTC)


 * Further, being a lot smarter than other people is a source of great dissatisfaction in life, but that's besides the point, whatever it was. 72.228.177.92 (talk) 12:16, 5 May 2011 (UTC)

Rotating model
If you keep your eyes focused on the moving toe you can usually catch each instance when you change the rotation direction, I think? Does that tell you anything?WFPM (talk) 04:08, 2 May 2011 (UTC)
 * No, the break simply happens at the repeat. But she rotates the same direction each time (though each 360 degree cycle), until your brain switches and decides to see the next set (however many there are) going the opposite way. You don't really see a new rotation direction every 360 degrees, do you? S  B Harris 05:35, 2 May 2011 (UTC)

I'll be darned!! I'm just paying attention to the fast moving foot, and at each break my mind tells me that she had to have changed the direction of rotation.


 * It appears that you make the selection unconsciously when you first see the image but it needs to be a new scene. I found she seems to switch feet if I switch contexts. Fascinating. 72.228.177.92 (talk) 21:56, 4 May 2011 (UTC)
 * You'll find that if you stare long enough, she can change direction even without you looking away-- it happens as you watch, at the "glitch." But it's yet another step from THAT to being able to mentally cause her to rotate either way, at will. I'm convinced this can be done, and sometimes I can do it after some effort, but still never immediately. S  B Harris 03:25, 5 May 2011 (UTC)

The first one I tried, with the transiting particles, took a while to find the break. But this one, with the moving foot, makes you decide on reversal because you know something happened and it could only be a reverse motion procedure, either in the image or in your mind. After all, the foot isn't moving at constant velocity but is speeding up in the center and stopping at the ends. And I'm pretty sure that's what she did. Of course, I can visualize her going either way, but this instant change at the break point jars my differential calculus capability related to which way people that I pay attention are moving. Of course, I'm not very skilled at calculus.WFPM (talk) 23:41, 5 May 2011 (UTC)

Your text indicates directions of rotation using counterclockwise and clockwise notations. With horizontal viewpoints and horizontal rotation these terms are meaningless with a vantage point specified. Since you are such a "perfection freak" I thought you may be interested in the definition clarity not normally used. From the top is usually assumed by most...LOL. I always laugh when people get caught on the "cup half full being a pessimist" thing. I was trying to empty the cup! This is my "segue" into needing an article on "magnesium bis gycinate". You seem like a very good candidate for an article of this nature. I have already been bullied and harrassed too many times to even attempt it. Thanks. Mixed message, or what? 99.251.114.120 (talk) 03:28, 13 March 2012 (UTC)
 * Terrible segue, that's for sure. Go ahead and start and article on Mg bisglycinate. Put in refs on absorption from peer-reviewed lit. We'll link it to magnesium in biology and some others. Right now it's not exactly a major Mg oral supplement. You'll have to convince me that anything does better than free Mg2+ ala MgCl2, since the going standard-model is that Mg is absorbed as Mg2+ and production of this species in the gut is the only real difference between supplements (and the reason of the failure of the insoluble ones). But I could be wrong.
 * I am making an awful mess of your page here. Magnesium bisglycinate is the main magnesium supplemnt sold here and most online stores, currently. That was the reason I was here to begin with. Any research I have done, todate, only shows up more spam and buy me, "it's wonderful", websites. You appeared to have all the right background for the subject of such an article. Trying the supplement personally I find no diarrhea problems (as with other compounds) and I believe the reason why it has become suddenly popular. Real data has been elusive to me. BTW: I know very little of chemistry or wiki methods. Thanks. 99.251.114.120 (talk) 21:23, 13 March 2012 (UTC)

As to the dancer, of course we assume the overhead vantagepoint for things where it's rather difficult to view from any other direction. Duh. If you look at your old-fashioned timepiece from underneath, the hands are running counterclockwise! The same happens if you view a spinning dancer from underground but that's going to happen even less often than looking at your watch from underneath, isn't it? So, you're being awfully pedantic. S B Harris 18:22, 13 March 2012 (UTC)
 * The dancer thing was a bit of a joke but exemplifies POV and lack of definition accuracy communication humours. 99.251.114.120 (talk) 21:23, 13 March 2012 (UTC)

Cosmic rays
BTW, cosmic rays are definitely NOT "stable particles" as mentioned in the article. In fact the former text was gross and simple minded, stomping all over the wave particle duality and stating that cosmic rays are particles which ere stable in the earth like electrons and protons which is just plain false, cosmic rays aren't stable, trapped in ordinary matter, like the subatomic entities that are justifiably viewed as particles, anywhere. 72.228.177.92 (talk) 12:13, 5 May 2011 (UTC)


 * You seem to have major misconceptions. "Stable" means not subject to spontaneous decay, like pions, muons, or neutrons are. Those things are found in secondary cosmic rays, but they don't last long enough to travel between stars, or even from the Sun, even with relativistic time dilation. So they are NOT in primary cosmic rays. This has absolutely NOTHING to do with wave-particle duality: all stable and unstable particles too have wave characteristics; this is a totally unconnected property.


 * Protons, electrons and their antiparticles are stable on timescales far longer than the life time of the universe (so long that we don't even know if protons ever decay). On earth, both these particles and antiparticles can be kept trapped in accelerator storage rings for a day or more, and that's not limited by stability, but by the mechanics of the trap. They last hundreds or thousands of years between stars-- perhaps millions. They compose nearly all primary cosmic rays. Nobody has convincingly found an unstable particle in a primary cosmic ray. Do some reading, please.  S  B Harris 17:06, 5 May 2011 (UTC)

If cosmic rays are not stable enough to have come from somewhere, then where did they originate?WFPM (talk) 22:17, 12 May 2011 (UTC)


 * They are stable enough to come from somewhere. That's the point. That's WHY they're made of stable particles. Though I once figured that a neutron with 100 J of energy would have a gamma of 10^11 or something, and be able to travel between galaxies without decaying. S  B Harris 00:23, 13 May 2011 (UTC)

You're confusing me! Is the thing acting in the earth's atmosphere a gamma cosmic ray from some distant galaxy, or else a neutron? And of course I'd be in favor of a local neutron, but I didn't think there were locally available loose neutrons. And I've heard about fast protons, but don't know what they do, except provide energy of transition for some reaction. And I guess I've just not got my mind working today, but I just cant see a gamma ray from a distant galaxy, either as a particle or a streams of small particles. Do we get gamma radiation from the Whirlpool Galaxy?WFPM (talk) 21:03, 14 May 2011 (UTC)


 * We get gamma rays from everywhere in the cosmos, including from incredibly energetic hypernova explosions 10 billion light years away. But those are not cosmic rays. Please read the article on cosmic rays. Secondary cosmic rays (produced newly in the atmosphere) contain unstable particles like pions, muons (the pion's favorite decay particle) and neutrons. But these are generated close to Earth and don't have far to travel (and the length they DO have to travel is shortened by relativity, in their reference frame; in our frame, they last longer due to relativistic time delay-- see muon). S  B Harris 23:36, 14 May 2011 (UTC)

Okay. trying to make method out of madness, we've got incoming primary (Cosmic),(electrostatically charged?)  particles (including electrons) from everywhere entering the atmosphere and creating secondary smaller particles in the earth's atmosphere, and no rays. And all of that is distinct from the electromagnetic light energy we receive from the Whirlpool Galaxy. And neutrons?. I guess Asimov didn't get around to write about all this stuff. But I appreciate the information.WFPM (talk) 14:22, 15 May 2011 (UTC)
 * Yes. Again, "ray" is an anachronistic term from the time when we had alpha rays and beta rays and cathode rays. It doesn't mean EM radiation. Cosmic rays are all charged particles (that's how they got accelerated to the speeds they need to get here). They are stable because it took them some time to get here, even with the help of relatativity. Finally, all that is no longer true in the atmosphere where newly made particles from all that energy, can be unstable ones and still make it to the surface detectors. S  B Harris 20:57, 15 May 2011 (UTC)

Verifiability not truth
Hello. I thought you might like to contribute to the discussion at: Village_pump_(policy). Biscuittin (talk) 14:54, 4 May 2011 (UTC)

WP:Government
I started WP:Government yesterday. This is intended to break long standing deadlocks on Wikipedia, if the community feels that the status quo is not good but they are divided on precisely how to move forward. I have in mind certain policy pages, or the creation of new policies that the community thinks are necessary, but which then never get started because of lack a of consensus for any particular proposal. The community can then elect a committee to move forward. If you are interested, you can expand/improve the proposed policy. Count Iblis (talk) 18:50, 11 May 2011 (UTC)

WP Elements in the Signpost
"WikiProject Report" would like to focus on WikiProject Elements for a Signpost article. This is an excellent opportunity to draw attention to your efforts and attract new members to the project. Would you be willing to participate in an interview? If so, here are the questions for the interview. Just add your response below each question and feel free to skip any questions that you don't feel comfortable answering. Other editors will also have an opportunity to respond to the interview questions. If you know anyone else who would like to participate in the interview, please share this with them. Have a great day. -Mabeenot (talk) 17:15, 5 June 2011 (UTC)

Color confinement animation
A few months ago, I added an animation to Nuclear Force. You liked it, and I later said that I'd try and make one for Color confinement. I did make one, but Flash wasn't lettimg me export it an animated GIF without compromising on some animated parts. I tried a lot, and then I gave up. Today, I figured out how to do it (with a very roundabout process), so I've uploaded the image. Tell me what you think, and if it needs any improvement. Thanks, Manish Earth Talk •  Stalk 06:21, 6 June 2011 (UTC)

Good change on the Freon
I agree with your changes and the rationale (commercial importance has plummetted...man that was a huge industry with a big change). I like the addition of the ozone depletion as that is a big topical thing and "lead worthy" and liked where you located it within the lead.

I might prefer not using the smelting term in lead (think in technical articles any time we can make the lead a little "easier" and use a simple term versus a complex one and avoid a blue link better. But this is pretty subtle preference and won't fight you.  I know you love your fluorospar in smelting!  TCO (talk) 02:18, 10 June 2011 (UTC)
 * If you want to change smelting to "metal extraction from ore" it's okay with me, but it's longer. I though "metal forming" was weird and sounded like forging-- not metal extraction, production, preparation, separation, isolation or whatever, from its compounds. It was clearly the wrong word but I didn't have a much better one. Doesn't everybody know what smelting is? This isn't Simple English Wikipedia, and it's not a very technical word. Is it? The big problem with Wikipedia is who is the audience. S  B Harris 03:01, 10 June 2011 (UTC)
 * Smelting is fine. I might de-wl it then, but I don't care.  I don't think it is a high gain term (for this article) and get concerned about over-blueing the lead.  Yeah forming is bad.  Maybe refining.  But really...smelting is fine.TCO (talk) 03:21, 10 June 2011 (UTC)

searching
Are you a physician? Camew across your name on some 1998 post, when I was doing a search for F smell (or maybe burns, can't recall).TCO (talk) 05:20, 16 June 2011 (UTC)


 * Yep. I've done an aweful lot of work pumping perfluorinated liquids into lungs, trying to find a way to cool the brain very rapidly for resusciation, and also to treat edema, drowning, smoke inhalation, etc. The liquids are VERY weird. Hence my interesting in fluorine chem (among many other interests). You have to actually touch some of this stuff (breathe this stuff) to believe it. You should watch a goldfish try to swim to the bottom of beaker half full of fluorocarbon liquid. They make it to the bottom, but have to swim like mad through the non-water, due to bouyancy (density is 1.8 g/ml). Then they pop up into the water again, none the worse for it. Much the same thing happens to lungs. If you've ever seen the film The Abyss, it's more or less like that. S  B Harris 05:25, 16 June 2011 (UTC)


 * Cool. We need a picture of an HF burn.  Can you advise of an academic or burn specialist or the like who would have some pics?  I am VERY used to writing and asking for donations.  Some of my turtle images required huge amounts of research to find pics and then a bunch of letters to get a donation.TCO (talk) 05:44, 16 June 2011 (UTC)


 * The person who did the F2 chemicals photo also had some contribs on perfluoronated stuff. (Yeah, I contrib stalked him.  Trying to check out the validity of the donation of the image.)TCO (talk) 05:45, 16 June 2011 (UTC)

Has anyone ever supercooled F2 to see if it has the same B+ instability characteristic at a low temperature, or maybe is a little more stable?WFPM (talk) 13:29, 18 June 2011 (UTC)

Wyatt Earp GAN
Wyatt Earp was listed as a GA in April, then went through a GAR and was delisted. It is now going through another GAN. Wyatt Earp is one of Wikipedia's most popular articles and is on an important and complex topic. The GAN is on an initial seven day hold while the reviewer checks sources. Meanwhile there is some work to be done on trimming back excessive detail, and on making the article flow more by reducing the amount of subsections. See Talk:Wyatt Earp/GA3 for more detail.  SilkTork  *Tea time 20:15, 16 June 2011 (UTC)

Revenge for caesium and aluminium?
The misspelling of sulphur as sulfur is your revenge for spelling caesium and aluminium like they should be spelled? Why shouldn't aluminium be spelled that way---we don't have radum, helum, lithum, and uranum, do we? And blue in Latin is csius, not cesius. You Yanks are insane, that's what you are :) --Nmatavka (talk) 20:34, 20 June 2011 (UTC)
 * But we do have helium, except it's not a metal. Nor, really, is selenium. And if you don't like aluminum, how can you live with molybdenum, lanthanum and platinum? And at the same time we have all kinds of certifiable metals (iron, copper, nickel, cobalt), even modern ones like tungsten, with no -ium. Yes, blue in early Latin is caesius, but spelled with an ae digraph. The ligature in Latin came only later, and the Old English digraph (with the history you can see in Ash (letter)) is a copy of that. But is that really a proper transliteration? And what are we going to do with all those digraphs like foetus and paediatrics? For that matter, if we're into scholarly transliteration of Greek έ into æ or ae, then why not xaenon and haelium? Public school priggishness, the lot of it. You know, it's not us Yanks that are crazy. (And by the way, IUPAC is preparing to kill caesium). S  B Harris 00:17, 21 June 2011 (UTC)
 * Where did you find that information about IUPAC preparing to change "caesium" to "cesium"? It sounds very interesting. It's been posted on Talk:Caesium/Spelling in January 2011, but nothing seems to have changed after a year. (Cæsium is a redirect.) Double sharp (talk) 14:06, 8 March 2012 (UTC)

Battleground
Statements like this: "User:Math.geek3.1415926, shame on you. The first article you edited when coming to WP was power law in 2009, one which has many sections still devoid of any citations at all to this day, as is typical for MOST math articles on WP. So, might I suggest that you return to the math articles and cause this kind of trouble there, and leave those of us who are interested in physics and engineering alone? Thanx." Are not helpful to anyone. I suggest you refrain from creating an adversarial situation when one isn't necessary, and tying the validity of a user's contributions to their past editting history is, frankly, tacky and even petty. Should I claim primacy over you for having been on wikipedia for longer, or should you do the same to me for having a higher edit count? Stick to the merits of the argument please, otherwise we'll all just start yelling at each other endlessly and unproductively. siafu (talk) 15:51, 21 July 2011 (UTC)
 * Well, that wouldn't be the first time that happened on WP, if we do. The "merits" of any case include who the editors are and how long they've been around. WP policy is an endless court of appeals and case law, and who the previous judges were, and what they did, always matters. Pointing out inconsistent behavior and even hypocrisy in another editor is always germane for this reason. If User:Math.geek3.1415926 is blind to the problems of noncitation in the types of articles he usually edits, or edited at first, but now wants to fix that stuff on the articles *I* edit, it's perfectly within my purvue to point that out. Since he's being so inconsistant and eratic (even by his own standards), obviously something is wrong and needs explaining. The idea that he can just follow one policy when he wants to, and the opposite policy when THAT pleases him, is unacceptable, and I won't put up with it. Nor should I. The question of much longer residence or edit counts on WP are sometimes relevant also, especially when some editor who has been around for more than 6 years (as we both have) seems to have missed some essential idea. I pointed out what I thought you'd missed, which is the central idea that we don't delete imperfect sections of articles until we can replace them with perfect ones. WP is not only a work in progress, but the warts are visible to all while it is. If you don't agree, I invite you to post an RfC on the subject of deleting entire unreferenced math sections in engineering articles, at one of the relevent working group pages, such as http://en.wikipedia.org/wiki/Wikipedia_talk:WikiProject_Spaceflight, and see what they think of it. Maybe they'll all agree with your position, who knows? If they do, I'll bow out. But if they don't I expect you to admit that you're trying to do something which isn't general historical policy.  S  B Harris 18:53, 21 July 2011 (UTC)
 * Contrary to what you've been claiming, there isn't a historical policy on this; what we're looking at the age-old debate between eventualism and immediatism, and as such it's not a central policy at all, but a particular philosophy of editting. Obviously we stand on opposite sides of this debate.  However, if you may recall, my argument against retaining that section as it is was not the lack of citations at all, but that it's a poorly written and not very helpful section.  My objection to your restoration also wasn't even based on that, but just based on the fact that your position seems to be strictly using a neutral argument in a positive sense: specifically, because lack of citations is (at least in your view) not a good enough reason to delete, it should be kept.  My view is that some justification should be present for its inclusion in addition to this neutral stance.  If we made a reductio of your position, as I am seeing it currently, it would be better to keep a section of gibberish in the hope that it might be improved than to remove it and limit an article to the well-written and verified sections.  I think you can agree that this definitely reaches the absurdam criterion, and if I'm misunderstanding, do let me know.  The extreme length of time that the article has languished without improvement seems to me to represent some strong evidence that the eventualist approach you're adopting here is not helping improve the article.


 * As for your treatment of this other use, I really couldn't give a fig what his (or your) past history is. He did present the point that this section has languished for almost a year without being improved, a point you choose to ignore in favor of attacking the user directly, and frankly that's not a good strategy to convince others (e.g. myself and all others who have commented so far), much less proper behavior in civil discourse in general.  That's why I brought it here to your talk page, also, and not on the article talkpage, as the point I wanted to make was also not relevant to the discussion, but a personal point.  If you want to request an RfC on his behavior, I assume you know the proper venue for that, and that you also know that that venue is not an article talk page. siafu (talk) 20:24, 21 July 2011 (UTC)

Help with calendar article
I noticed you commented intelligently on Gregorian calendar, and I'm hoping you can help with a dispute over Perpetual Calendar. If you check out the Discussion page, at the bottom you'll see the argument I've gotten into with a non-logged-in IP user who refuses to allow edits to his pet article. He insists that what he calls the "Exigian" calendar, which changes the Gregorian rule for '00 leap years, is the correct reckoning to use, and keeps reverting my efforts to make the article accurate for both Julian and Gregorian dates. My position is that if the article is to exist, it must at least cover the Gregorian calendar that is widely accepted throughout the world. If there were consensus to also include this "Exigian" proposal, (which not only has never been adopted by any country, scientific, religious, or other standards body, but doesn't even have an article on Wikipedia) that would be one thing, but it cannot cover this speculative system to the exclusion of the existing world standard. So far, it's been a one-on-one dispute, and before I resort to asking for arbitration, I'd like to get some other editors involved in the discussion. Maybe if a few of the knowledgeable editors from Gregorian Calendar would indicate their opinion on excluding Gregorian in favor of "Exigian", (s)he will stop asserting that there is some kind of consensus to do so.The Monster (talk) 14:24, 16 September 2011 (UTC)

Sorry... can't resist...
Hi SB:

Sorry I engaged Gil... just can't resist... and I know it's a complete waste of time. I'm kinda surprised his stuff hasn't already been removed, and I can't be the one who does it.

Keep up the good work, you've always good great points to deflate their arguments!

Cheers

Jeremy aka CJ Canada Jack (talk) 18:57, 16 September 2011 (UTC)


 * That's okay. As I said, I actually don't mind this sort of thing, even if not technically "WP legal" if it's short, concise, and honest. Per WP:IAR, sometimes that kind of thing DOES improve the article, as for example the new dictabelt evidence that the HSCA kept ignoring after it adjourned. And the best assassination recreations (save for the audio one that HSCA did) have actually NOT been done by official agencies, which poses a problem to articles like this one. Editors just have to use their judgement as to who has done a really bang-up job of this. So critics have their place! I only demand that they be honest and concise ones, and almost always, they aren't. Jesus isn't. S  B Harris 19:06, 16 September 2011 (UTC)

Triglycerides for everyman
We have triglycerides and related fats fixed up semi-ok chemically, but of course readers are checking here to understand their blood tests not to get a refresher on organic chemistry. For example we got this note Talk:triglyceride. All that I know is that triglycerides are catabolized back through acetate as a source of energy, but we need some source and some help for normal people. Is there any chance you could add a sentence or three to the lead of this article? Thanks, --Smokefoot (talk) 13:29, 22 September 2011 (UTC)
 * I'll see what I can do when I get off the road and this blasted laptop after Monday. The problem is that we ask this (now) small article to do a lot-- not just cover the many oils and fats as chemicals,  but also the disease part. In the cholesterol article the subject chemical isn't nearly as important as a bulk industrial product, whereas plant oils and animal fats are gigantic industries all by themselves. We'll have to ask hypertriglyceridemia to do a lot more work as a WP:SS subarticle than for the cholesterol case, and so on. And sure, we can (must) put in some more energy metabolism summary here in the trigyceride LEDE.  S  B Harris 05:54, 24 September 2011 (UTC)

Norman Walker
You may feel you can restore anything you like, but all that text, and the only reference being "Pure and Simple Natural Weight Control, copyright 1981", that's ridiculous. Please see WP:CITE, and then see WP:V. I won't revert, but if this abomination is kept I'll go through it with a fine comb. Drmies (talk) 22:14, 7 October 2011 (UTC)
 * If you do, you'll be doing a service, as I don't have a copy of Pure and Simple Natural Weight Control so it's hard for me to tell what is and what isn't in it. It's not beyond the bounds of belief that all this stuff IS in it, as Walker does tend to repeat himself. The suggested density of citations on WP is about one per paragraph, but the world won't end if you only have one per two or three paragraphs, so long as all the stuff IS summarized in the cited source.
 * You may have missed my own interest in getting all this stuff into Wikipedia. I'm interested in the history of ideas in health, including alternative ideas that are very popular. Somebody needs to know where all this comes from, and on whose "authority." I think Walker is a huge source of all this "colon detoxification" stuff that actually started with Élie Metchnikoff's theories on "colon toxins" and autoimmunity. From Walker (and Kellogg) it goes through Gerson and on down to every Tijuana coffee enema clinic. And shows up in the teachings of people like the late Jack LaLanne. Gerson was something of a quack, but I can't really say that about LaLanne. LaLanne's ideas aren't all that far from those of Dean Ornish, and T. Colin Campbell and LaLanne considerably preceeds them. The dialogue on what to eat that was in part started by Walker has continued films like Forks Over Knives and (more to the present point), the recent commentary "Fat, Sick and Nearly Dead." It's all been very necessary. The American diet is not very good, and the "establishment" (the government, corporate food production, and the medical establishement) has been more or less unhelpful. Say what you will, the reality is that in America we live in a nation of fast food, soda pop, cardiac bypass, and Lipitor (posterboy former president Bill Clinton). The USDA continues to be a paid advocate for meat-eating, and they're now pushing 6 food groups . In such a country it's not a good place to be pointing fingers at juice advocates, who are (basically) just fruit and vegetable advocates, in a way that allows an even larger fraction of nutrition to come from those sources that eating them whole. For the average American, moving in that direction may not be so crazy. Certainly many need more help than they are getting. Anyway, I am simply interested in documenting where these ideas came from, even if some of the holders of them didn't have advanced degrees, and perhaps had some gonzo ideas, too. After all, who doesn't? S  B Harris 23:24, 7 October 2011 (UTC)

Summarize Edits
Could you summarize your edits, so they don't come across as vandalism? Thanks for cleaning up a lot of articles.Carstensen (talk) 17:20, 16 October 2011 (UTC)

Ahoy there...science
Debate has started anew to get science to GA or FA status. Join in the fun at Talk:Science and scroll down...we'll try not to reinvent the wheel Casliber (talk · contribs) 01:22, 17 October 2011 (UTC)

Why did you...
Edit my contribution? [] --Damorbel (talk) 20:05, 27 October 2011 (UTC)


 * The diff shows I effectively did, but you see what happened is mere deletion of this text: observed at the collective or bulk level. It is the gas constant R divided by the Avogadro constant NA.  That simply got deleted in your comment, in the same edit that I added my comment below. The only explanation I have for a simple deletion like that in a comment not mine, is the old standby of a cat on the keyboard standing on the delete key briefly, while I was typing in edit mode. I know it sounds like "dog ate my homework" but that is probably exactly what happened. Sorry! I've re-inserted it. S  B Harris 22:00, 27 October 2011 (UTC)

OK. --Damorbel (talk) 06:58, 28 October 2011 (UTC)

Why did you (2)...
Change my contribution ? Your changes alter the basis of my argument and my efforts to improve the article. Please reverse them and restore the text to that of my contribution - please. --Damorbel (talk) 20:52, 29 October 2011 (UTC)
 * As I promised, I restored your comment to its original condition before my accidental deletion of a line. If you check the following diff, you can see that it NOW looks exactly the same as when you finished it, except for a missing period in your quote, which is now there. . And if you don't like what it says now, feel free to fix it up any way you like. S  B Harris 18:07, 30 October 2011 (UTC)

Neutral buoyancy
Hi Steve, I saw your concerns about the buoyancy calculations at Buoyancy compensator (diving) which took the entire contents of the cylinder into account when weighting for neutral buoyancy. There's a reason for that, which is to account for the worst case. For example, in the event of a failure of a dive computer during a dive, the procedure which gives the greatest margin to avoid DCS is to abort the dive, ascend to the likely shallow stop depth (3 metres or 10 feet usually), and breathe out your cylinder before surfacing. If you arrange to be neutrally buoyant at 500 psi (or 50 bar for the UK), then you will be positively buoyant when the tank pressure is lower than that, and will have more difficulty in maintaining a stop depth. Being a little bit negatively buoyant is much easier to cope with, by deploying a DSMB and/or putting a little air into the BCD.

I agree that everybody should have a backup plan derived from tables, and a backup timing device, but the truth is that many divers have no such fallback. There are other scenarios (e.g. 'O' ring fails on ascent, buddy donates air) where divers want to make a shallow deco or safety stop with a near-empty cylinder and it simply makes sense to recommend that divers weight for the worst-case buoyancy possible, rather than what their buoyancy ought to be if everything went to plan and they had their reserve gas left. Cheers, --RexxS (talk) 02:15, 4 November 2011 (UTC)
 * Okay, I like your argument, though the difference is only the 1.5 pounds you MIGHT breathe if you totally blow your deco or have some emergency and have to go to zero psi at 10 fsw. If that happens, the 1.5 lbs from that last 500 psi might be the least of your worries, but I can envision somebody who is soooo perfectly weighted, that that LAAAST 1.5 lbs puts them positive, so that they can't stay down to breathe their safety gas. Yeah, I've seen it. Hmmmm. Well, no, now that I think of it, I haven't. I've had many underweighted dives where I couldn't get down at the first of the dive. I've had many a few underweighted dives, where I got "down," but found out I was starting to get positive halfway through the dive-- but it was long before I was close to desperately breathing my last reserves. Usually I've picked up a rock or hung onto the old buddy at the safety stop (or stolen a weight, etc). Generally, people know they're in bouyancy trouble long before the end of the dive, since they can't get down with the puffed up wetsuit at the very beginning. But not because the total tank loss gets them at the end. Usually (at least with an Al-80) you've burped enough gas from your wetsuit and that last bit from your BC at depth (a matter of 2 quarts of air), to make up for most of the mass of what you breathe during a dive (as you know). Anyway, feel free to change it back. I don't think it's enough to argue over if ANYBODY doesn't like it, including of course you. Happy divin. (Soon to be diving Phuket, Thailand. Tongue out, raspberry) S  B Harris 02:32, 4 November 2011 (UTC)
 * Nah, leave it be - the 1.5 lbs of buoyancy is rather less than a litre of air in your lungs, and I've seen tension from coping with problems make more than that amount of difference. I just thought you'd be interested in what the theoretical recommendations are: you also weight yourself to include any positively buoyant equipment (camera in housing, etc.), but not including negatively buoyant equipment (big torches, etc.) just in case you lose those during the dive! Phuket ... you lucky, lucky *@**!?* :D Dive Safe, --RexxS (talk) 03:00, 4 November 2011 (UTC)

Wrong!
Well, why do you write beryllium-10 as Be-10, not 10Be, like how it should? For doing that, you get this:


 * 1) EFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEFEF
 * 2) AAAAAAAAA!
 * =[|) SPLAT!
 * 1) SHUSH!
 * 1) SHUSH!

There "U" go! >:( 3.14159265358pi (talk) 01:22, 22 November 2011 (UTC)


 * Writing elements as symbols with the mass number after may not be approved by IUPAC today, but it's extremely common since it was once the standard. I fail to see why you can write beryllium-10 or uranium-238, but are forbidden to write Be-10 or U-238. That's just stupid. I don't know when it stopped historically. For example, here's a 1956 paper with "U-235" in the title in Physical Review, by Richard Feynman. . That's a pretty prestigious author and journal. S  B Harris 02:10, 22 November 2011 (UTC)

Effective dose
Please stop editing the effective dose articles. You are not doing it correctly. I see what you are attempting, and I think it's a good idea, but here is how to do:

1. Remove the radiology content from Effective dose

2. Add that info to the new radiology article

3. Add WP:Hatnotes to the top of each page

4. Blank the new Effective dose (disambiguation) and request it be deleted. DAB pages are not used when there are only two pages and one has a plain title (Effective dose).

Thanks!! jsfouche &#9789;&#9790; Talk 20:17, 25 November 2011 (UTC)
 * P.S. Also, blank and request to delete the Effective dose (pharmacology) article as that content will remain in the Effective dose article once you remove all the radiology info.  jsfouche &#9789;&#9790; Talk 20:19, 25 November 2011 (UTC)

There will be be three articles, as there is an "effective dose" used in radiology to get proper exposures. And I am sure that there are many other uses of the term "effective dose" as well. A dab page is inevitable. Are you doing to help or hinder? S B Harris 20:31, 25 November 2011 (UTC)

Note to self

 * Later: user:zzuuzz has "schoolblocked" it. Way to go, zzuuzz! S  B Harris 20:13, 17 November 2011 (UTC)
 * Come talk to me if there's a need, as well, Sbharris. And we do our best but we have limited resources and aren't paid.--Wehwalt (talk) 20:32, 17 November 2011 (UTC)
 * We are always available for IAR. Still, how about loosining up the criteria to alot of warnings.    Ebe 123   → report ← Contribs 21:40, 17 November 2011 (UTC)
 * Thanks, you're both going on my "goto" list for outrageous IP pages full of warnings that haven't been blocked because somebody is afraid it will keep the kids from editing.

Answer: why does his pipelink above read ...
Hi, posting here because responding at WT:IRS would be off topic. It's kinda technical - I don't know how well up you are on how Wikipedia linking works behind the scenes.

In response to your query "if he meant footnote 5, why does his pipelink above read footnote ?", that is normal for Wikipedia footnote links - although the visible numbering begins at 1, the hidden numbering begins at 0. Such links consist of the URL for the page itself, then a # symbol, then the anchor within the page. The anchor consists of the two words, then a hyphen and finally an integer; if the reference is named (as in ), that name is inserted, with another hyphen, before the terminal integer.

This can be checked by going to almost any article which provides links in main text to the footnotes/refs by displaying a superscripted [1] etc. Pick one of these, note the number, then hover your mouse over that link; the grey strip at the bottom of the browser window should show the URL of the link (if it doesn't, click the link, and your browser's address bar should show the URL). Right at the end of the URL you should see the hyphen and integer; and that integer will be one less than the number of the ref link which you noted. For example, the first footnote in today's featured article is reached as School for Creative and Performing Arts and the sixth is School for Creative and Performing Arts. -- Red rose64 (talk) 15:21, 1 December 2011 (UTC)

30,000 edits
Only one away now! StringTheory11 22:51, 11 December 2011 (UTC)

Diamagnetism
I have to run and can't give a detailed answer, but read around on that (I have to do that as well). We'll have to reflect this in elements articles. Materialscientist (talk) 02:07, 18 December 2011 (UTC)